trial_id,variable_label,variable_label_raw,categorical_label,variable_type,units,arm_label,arm_role,arm_total_n,n,percent,mean,sd,raw_value
NCT01272219,Sex,Sex — no. (%),,categorical,,Liraglutide,treatment,2487,1957,78.7,0.0,0.0,1957 (78.7)
NCT01272219,Sex,Sex — no. (%),,categorical,,Placebo,control,1244,971,78.1,0.0,0.0,971 (78.1)
NCT01272219,Age,Age — yr,,continuous,years,Liraglutide,treatment,2487,0,0.0,45.2,12.1,45.2±12.1
NCT01272219,Age,Age — yr,,continuous,years,Placebo,control,1244,0,0.0,45.0,12.0,45.0±12.0
NCT01272219,Race or ethnic group,Race or ethnic group — no. (%),,categorical,,Liraglutide,treatment,2487,2107,84.7,0.0,0.0,2107 (84.7)
NCT01272219,Race or ethnic group,Race or ethnic group — no. (%),,categorical,,Placebo,control,1244,1061,85.3,0.0,0.0,1061 (85.3)
NCT01272219,Weight,Weight — kg,,continuous,kg,Liraglutide,treatment,2487,0,0.0,106.2,21.2,106.2±21.2
NCT01272219,Weight,Weight — kg,,continuous,kg,Placebo,control,1244,0,0.0,106.2,21.7,106.2±21.7
NCT01272219,Body-mass index,Body-mass index,,continuous,,Liraglutide,treatment,2487,0,0.0,38.3,6.4,38.3±6.4
NCT01272219,Body-mass index,Body-mass index,,continuous,,Placebo,control,1244,0,0.0,38.3,6.3,38.3±6.3
NCT01272219,Waist circumference,Waist circumference — cm,,continuous,cm,Liraglutide,treatment,2487,0,0.0,115.0,14.4,115.0±14.4
NCT01272219,Waist circumference,Waist circumference — cm,,continuous,cm,Placebo,control,1244,0,0.0,114.5,14.3,114.5±14.3
NCT01272219,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Liraglutide,treatment,2487,0,0.0,5.6,0.4,5.6±0.4
NCT01272219,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Placebo,control,1244,0,0.0,5.6,0.4,5.6±0.4
NCT01272219,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,95.9,10.6,95.9±10.6
NCT01272219,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,Placebo,control,1244,0,0.0,95.5,9.8,95.5±9.8
NCT01272219,Fasting insulin,Fasting insulin — μIU/ml,,continuous,μIU/ml,Liraglutide,treatment,2487,0,0.0,16.3,79.8,16.3±79.8
NCT01272219,Fasting insulin,Fasting insulin — μIU/ml,,continuous,μIU/ml,Placebo,control,1244,0,0.0,16.1,89.3,16.1±89.3
NCT01272219,Blood pressure,Blood pressure — mm Hg,,continuous,mm Hg,Liraglutide,treatment,2487,0,0.0,123.0,12.9,123.0±12.9
NCT01272219,Blood pressure,Blood pressure — mm Hg,,continuous,mm Hg,Placebo,control,1244,0,0.0,123.2,12.8,123.2±12.8
NCT01272219,Cholesterol,Cholesterol — mg/dl,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,193.7,19.1,193.7±19.1
NCT01272219,Cholesterol,Cholesterol — mg/dl,,continuous,mg/dl,Placebo,control,1244,0,0.0,194.3,18.8,194.3±18.8
NCT01272219,LDL,LDL,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,111.6,27.9,111.6±27.9
NCT01272219,LDL,LDL,,continuous,mg/dl,Placebo,control,1244,0,0.0,112.2,27.6,112.2±27.6
NCT01272219,HDL,HDL,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,51.4,26.2,51.4±26.2
NCT01272219,HDL,HDL,,continuous,mg/dl,Placebo,control,1244,0,0.0,51.0,26.4,51.0±26.4
NCT01272219,VLDL,VLDL,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,25.1,49.6,25.1±49.6
NCT01272219,VLDL,VLDL,,continuous,mg/dl,Placebo,control,1244,0,0.0,25.7,49.4,25.7±49.4
NCT01272219,Free fatty acids,Free fatty acids — mmol/liter,,continuous,mmol/liter,Liraglutide,treatment,2487,0,0.0,0.45,40.5,0.45±40.5
NCT01272219,Free fatty acids,Free fatty acids — mmol/liter,,continuous,mmol/liter,Placebo,control,1244,0,0.0,0.46,39.7,0.46±39.7
NCT01272219,Triglycerides,Triglycerides — mg/dl,,continuous,mg/dl,Liraglutide,treatment,2487,0,0.0,126.2,56.9,126.2±56.9
NCT01272219,Triglycerides,Triglycerides — mg/dl,,continuous,mg/dl,Placebo,control,1244,0,0.0,128.9,61.0,128.9±61.0
NCT01272219,Prediabetes,Prediabetes — no. (%),,categorical,,Liraglutide,treatment,2487,1528,61.4,0.0,0.0,1528 (61.4)
NCT01272219,Prediabetes,Prediabetes — no. (%),,categorical,,Placebo,control,1244,757,60.9,0.0,0.0,757 (60.9)
NCT01272219,Dyslipidemia,Dyslipidemia — no. (%),,categorical,,Liraglutide,treatment,2487,737,29.6,0.0,0.0,737 (29.6)
NCT01272219,Dyslipidemia,Dyslipidemia — no. (%),,categorical,,Placebo,control,1244,359,28.9,0.0,0.0,359 (28.9)
NCT01272219,Hypertension,Hypertension — no. (%),,categorical,,Liraglutide,treatment,2487,850,34.2,0.0,0.0,850 (34.2)
NCT01272219,Hypertension,Hypertension — no. (%),,categorical,,Placebo,control,1244,446,35.9,0.0,0.0,446 (35.9)
NCT03495102,Age,Age (years),,continuous,years,DU 1.5 mg,treatment,612,0,0.0,57.8,9.7,57.8 6 9.7
NCT03495102,Age,Age (years),,continuous,years,DU 3.0 mg,treatment,616,0,0.0,56.9,10.2,56.9 6 10.2
NCT03495102,Age,Age (years),,continuous,years,DU 4.5 mg,treatment,614,0,0.0,56.6,10.2,56.6 6 10.2
NCT03495102,Age,Age (years),,continuous,years,Total,other,1842,0,0.0,57.1,10.0,57.1 6 10.0
NCT03495102,Duration of diabetes,Duration of diabetes (years),,continuous,years,DU 1.5 mg,treatment,612,0,0.0,7.6,5.8,7.6 6 5.8
NCT03495102,Duration of diabetes,Duration of diabetes (years),,continuous,years,DU 3.0 mg,treatment,616,0,0.0,7.6,5.5,7.6 6 5.5
NCT03495102,Duration of diabetes,Duration of diabetes (years),,continuous,years,DU 4.5 mg,treatment,614,0,0.0,7.7,5.8,7.7 6 5.8
NCT03495102,Duration of diabetes,Duration of diabetes (years),,continuous,years,Total,other,1842,0,0.0,7.6,5.7,7.6 6 5.7
NCT03495102,Female sex,Female sex,Sex,categorical,,DU 1.5 mg,treatment,612,314,51.3,0.0,0.0,314 (51.3)
NCT03495102,Female sex,Female sex,Sex,categorical,,DU 3.0 mg,treatment,616,288,46.8,0.0,0.0,288 (46.8)
NCT03495102,Female sex,Female sex,Sex,categorical,,DU 4.5 mg,treatment,614,296,48.2,0.0,0.0,296 (48.2)
NCT03495102,Female sex,Female sex,Sex,categorical,,Total,other,1842,898,48.8,0.0,0.0,898 (48.8)
NCT03495102,Race,American Indian or Alaska Native,Race,categorical,,DU 1.5 mg,treatment,612,30,4.9,0.0,0.0,30 (4.9)
NCT03495102,Race,American Indian or Alaska Native,Race,categorical,,DU 3.0 mg,treatment,616,26,4.2,0.0,0.0,26 (4.2)
NCT03495102,Race,American Indian or Alaska Native,Race,categorical,,DU 4.5 mg,treatment,614,32,5.2,0.0,0.0,32 (5.2)
NCT03495102,Race,American Indian or Alaska Native,Race,categorical,,Total,other,1842,88,4.8,0.0,0.0,88 (4.8)
NCT03495102,Race,Asian,Race,categorical,,DU 1.5 mg,treatment,612,13,2.1,0.0,0.0,13 (2.1)
NCT03495102,Race,Asian,Race,categorical,,DU 3.0 mg,treatment,616,18,2.9,0.0,0.0,18 (2.9)
NCT03495102,Race,Asian,Race,categorical,,DU 4.5 mg,treatment,614,14,2.3,0.0,0.0,14 (2.3)
NCT03495102,Race,Asian,Race,categorical,,Total,other,1842,45,2.4,0.0,0.0,45 (2.4)
NCT03495102,Race,Black,Race,categorical,,DU 1.5 mg,treatment,612,28,4.6,0.0,0.0,28 (4.6)
NCT03495102,Race,Black,Race,categorical,,DU 3.0 mg,treatment,616,31,5.0,0.0,0.0,31 (5.0)
NCT03495102,Race,Black,Race,categorical,,DU 4.5 mg,treatment,614,23,3.7,0.0,0.0,23 (3.7)
NCT03495102,Race,Black,Race,categorical,,Total,other,1842,82,4.5,0.0,0.0,82 (4.5)
NCT03495102,Race,Native Hawaiian or Pacific Islander,Race,categorical,,DU 1.5 mg,treatment,612,1,0.2,0.0,0.0,1 (0.2)
NCT03495102,Race,Native Hawaiian or Pacific Islander,Race,categorical,,DU 3.0 mg,treatment,616,1,0.2,0.0,0.0,1 (0.2)
NCT03495102,Race,Native Hawaiian or Pacific Islander,Race,categorical,,DU 4.5 mg,treatment,614,3,0.5,0.0,0.0,3 (0.5)
NCT03495102,Race,Native Hawaiian or Pacific Islander,Race,categorical,,Total,other,1842,5,0.3,0.0,0.0,5 (0.3)
NCT03495102,Race,White,Race,categorical,,DU 1.5 mg,treatment,612,529,86.4,0.0,0.0,529 (86.4)
NCT03495102,Race,White,Race,categorical,,DU 3.0 mg,treatment,616,521,84.6,0.0,0.0,521 (84.6)
NCT03495102,Race,White,Race,categorical,,DU 4.5 mg,treatment,614,530,86.3,0.0,0.0,530 (86.3)
NCT03495102,Race,White,Race,categorical,,Total,other,1842,1580,85.8,0.0,0.0,1580 (85.8)
NCT03495102,Race,Multiple,Race,categorical,,DU 1.5 mg,treatment,612,11,1.8,0.0,0.0,11 (1.8)
NCT03495102,Race,Multiple,Race,categorical,,DU 3.0 mg,treatment,616,19,3.1,0.0,0.0,19 (3.1)
NCT03495102,Race,Multiple,Race,categorical,,DU 4.5 mg,treatment,614,12,2.0,0.0,0.0,12 (2.0)
NCT03495102,Race,Multiple,Race,categorical,,Total,other,1842,42,2.3,0.0,0.0,42 (2.3)
NCT03495102,HbA1c,HbA1c (%),,continuous,%,DU 1.5 mg,treatment,612,0,0.0,8.6,0.9,8.6 6 0.9
NCT03495102,HbA1c,HbA1c (%),,continuous,%,DU 3.0 mg,treatment,616,0,0.0,8.6,1.0,8.6 6 1.0
NCT03495102,HbA1c,HbA1c (%),,continuous,%,DU 4.5 mg,treatment,614,0,0.0,8.6,0.9,8.6 6 0.9
NCT03495102,HbA1c,HbA1c (%),,continuous,%,Total,other,1842,0,0.0,8.6,1.0,8.6 6 1.0
NCT03495102,BMI,BMI (kg/m2),,continuous,kg/m2,DU 1.5 mg,treatment,612,0,0.0,34.4,6.4,34.4 6 6.4
NCT03495102,BMI,BMI (kg/m2),,continuous,kg/m2,DU 3.0 mg,treatment,616,0,0.0,34.3,6.2,34.3 6 6.2
NCT03495102,BMI,BMI (kg/m2),,continuous,kg/m2,DU 4.5 mg,treatment,614,0,0.0,34.0,6.2,34.0 6 6.2
NCT03495102,BMI,BMI (kg/m2),,continuous,kg/m2,Total,other,1842,0,0.0,34.2,6.3,34.2 6 6.3
NCT03495102,Weight,Weight (kg),,continuous,kg,DU 1.5 mg,treatment,612,0,0.0,95.5,20.2,95.5 6 20.2
NCT03495102,Weight,Weight (kg),,continuous,kg,DU 3.0 mg,treatment,616,0,0.0,96.3,20.1,96.3 6 20.1
NCT03495102,Weight,Weight (kg),,continuous,kg,DU 4.5 mg,treatment,614,0,0.0,95.4,20.6,95.4 6 20.6
NCT03495102,Weight,Weight (kg),,continuous,kg,Total,other,1842,0,0.0,95.7,20.3,95.7 6 20.3
NCT03495102,eGFR,eGFR (mL/min/1.73 m2),,continuous,mL/min/1.73 m2,DU 1.5 mg,treatment,612,0,0.0,93.4,18.2,93.4 6 18.2
NCT03495102,eGFR,eGFR (mL/min/1.73 m2),,continuous,mL/min/1.73 m2,DU 3.0 mg,treatment,616,0,0.0,93.3,17.8,93.3 6 17.8
NCT03495102,eGFR,eGFR (mL/min/1.73 m2),,continuous,mL/min/1.73 m2,DU 4.5 mg,treatment,614,0,0.0,93.7,18.3,93.7 6 18.3
NCT03495102,eGFR,eGFR (mL/min/1.73 m2),,continuous,mL/min/1.73 m2,Total,other,1842,0,0.0,93.5,18.1,93.5 6 18.1
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 1.5 mg,treatment,612,33,5.4,0.0,0.0,33 (5.4)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 3.0 mg,treatment,616,25,4.1,0.0,0.0,25 (4.1)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 4.5 mg,treatment,614,33,5.4,0.0,0.0,33 (5.4)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,Total,other,1842,91,4.9,0.0,0.0,91 (4.9)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 1.5 mg,treatment,612,171,27.9,0.0,0.0,171 (27.9)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 3.0 mg,treatment,616,198,32.1,0.0,0.0,198 (32.1)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 4.5 mg,treatment,614,184,30.0,0.0,0.0,184 (30.0)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,Total,other,1842,553,30.0,0.0,0.0,553 (30.0)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 1.5 mg,treatment,612,408,66.7,0.0,0.0,408 (66.7)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 3.0 mg,treatment,616,393,63.8,0.0,0.0,393 (63.8)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,DU 4.5 mg,treatment,614,397,64.7,0.0,0.0,397 (64.7)
NCT03495102,eGFR category,eGFR category (mL/min/1.73 m2),eGFR category,categorical,mL/min/1.73 m2,Total,other,1842,1198,65.0,0.0,0.0,1198 (65.0)
NCT03495102,SBP,SBP (mmHg),,continuous,mmHg,DU 1.5 mg,treatment,612,0,0.0,132.1,14.2,132.1 6 14.2
NCT03495102,SBP,SBP (mmHg),,continuous,mmHg,DU 3.0 mg,treatment,616,0,0.0,131.1,14.1,131.1 6 14.1
NCT03495102,SBP,SBP (mmHg),,continuous,mmHg,DU 4.5 mg,treatment,614,0,0.0,132.1,14.0,132.1 6 14.0
NCT03495102,SBP,SBP (mmHg),,continuous,mmHg,Total,other,1842,0,0.0,131.8,14.1,131.8 6 14.1
NCT03495102,DBP,DBP (mmHg),,continuous,mmHg,DU 1.5 mg,treatment,612,0,0.0,78.8,9.3,78.8 6 9.3
NCT03495102,DBP,DBP (mmHg),,continuous,mmHg,DU 3.0 mg,treatment,616,0,0.0,78.4,8.7,78.4 6 8.7
NCT03495102,DBP,DBP (mmHg),,continuous,mmHg,DU 4.5 mg,treatment,614,0,0.0,79.0,9.0,79.0 6 9.0
NCT03495102,DBP,DBP (mmHg),,continuous,mmHg,Total,other,1842,0,0.0,78.7,9.0,78.7 6 9.0
NCT03495102,HR,HR (bpm),,continuous,bpm,DU 1.5 mg,treatment,612,0,0.0,75.6,10.1,75.6 6 10.1
NCT03495102,HR,HR (bpm),,continuous,bpm,DU 3.0 mg,treatment,616,0,0.0,75.3,9.5,75.3 6 9.5
NCT03495102,HR,HR (bpm),,continuous,bpm,DU 4.5 mg,treatment,614,0,0.0,75.5,10.3,75.5 6 10.3
NCT03495102,HR,HR (bpm),,continuous,bpm,Total,other,1842,0,0.0,75.5,10.0,75.5 6 10.0
NCT03495102,FSG,FSG (mg/dL),,continuous,mg/dL,DU 1.5 mg,treatment,612,0,0.0,185.0,52.0,185.0 6 52.0
NCT03495102,FSG,FSG (mg/dL),,continuous,mg/dL,DU 3.0 mg,treatment,616,0,0.0,184.0,54.4,184.0 6 54.4
NCT03495102,FSG,FSG (mg/dL),,continuous,mg/dL,DU 4.5 mg,treatment,614,0,0.0,183.4,48.0,183.4 6 48.0
NCT03495102,FSG,FSG (mg/dL),,continuous,mg/dL,Total,other,1842,0,0.0,184.1,51.5,184.1 6 51.5
NCT03548935,Age,Age — yr,,continuous,years,Semaglutide,treatment,1306,0,0.0,46.0,13.0,46±13
NCT03548935,Age,Age — yr,,continuous,years,Placebo,control,655,0,0.0,47.0,12.0,47±12
NCT03548935,Female sex,Female sex — no. (%),,categorical,,Semaglutide,treatment,1306,955,73.1,0.0,0.0,955 (73.1)
NCT03548935,Female sex,Female sex — no. (%),,categorical,,Placebo,control,655,498,76.0,0.0,0.0,498 (76.0)
NCT03548935,Race or ethnic group,White,Race or ethnic group,categorical,,Semaglutide,treatment,1306,973,74.5,0.0,0.0,973 (74.5)
NCT03548935,Race or ethnic group,White,Race or ethnic group,categorical,,Placebo,control,655,499,76.2,0.0,0.0,499 (76.2)
NCT03548935,Race or ethnic group,Asian,Race or ethnic group,categorical,,Semaglutide,treatment,1306,181,13.9,0.0,0.0,181 (13.9)
NCT03548935,Race or ethnic group,Asian,Race or ethnic group,categorical,,Placebo,control,655,80,12.2,0.0,0.0,80 (12.2)
NCT03548935,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,Semaglutide,treatment,1306,72,5.5,0.0,0.0,72 (5.5)
NCT03548935,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,Placebo,control,655,39,6.0,0.0,0.0,39 (6.0)
NCT03548935,Race or ethnic group,Other,Race or ethnic group,categorical,,Semaglutide,treatment,1306,80,6.1,0.0,0.0,80 (6.1)
NCT03548935,Race or ethnic group,Other,Race or ethnic group,categorical,,Placebo,control,655,37,5.6,0.0,0.0,37 (5.6)
NCT03548935,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),,categorical,,Semaglutide,treatment,1306,150,11.5,0.0,0.0,150 (11.5)
NCT03548935,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),,categorical,,Placebo,control,655,86,13.1,0.0,0.0,86 (13.1)
NCT03548935,Body weight,Body weight — kg,,continuous,kg,Semaglutide,treatment,1306,0,0.0,105.4,22.1,105.4±22.1
NCT03548935,Body weight,Body weight — kg,,continuous,kg,Placebo,control,655,0,0.0,105.2,21.5,105.2±21.5
NCT03548935,Body-mass index,Body-mass index‡,,continuous,,Semaglutide,treatment,1306,0,0.0,37.8,6.7,37.8±6.7
NCT03548935,Body-mass index,Body-mass index‡,,continuous,,Placebo,control,655,0,0.0,38.0,6.5,38.0±6.5
NCT03548935,Waist circumference,Waist circumference — cm,,continuous,cm,Semaglutide,treatment,1306,0,0.0,114.6,14.8,114.6±14.8
NCT03548935,Waist circumference,Waist circumference — cm,,continuous,cm,Placebo,control,655,0,0.0,114.8,14.4,114.8±14.4
NCT03548935,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Semaglutide,treatment,1306,0,0.0,5.7,0.3,5.7±0.3
NCT03548935,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Placebo,control,655,0,0.0,5.7,0.3,5.7±0.3
NCT03548935,Prediabetes,Prediabetes — no. (%)§,,categorical,,Semaglutide,treatment,1306,593,45.4,0.0,0.0,593 (45.4)
NCT03548935,Prediabetes,Prediabetes — no. (%)§,,categorical,,Placebo,control,655,263,40.2,0.0,0.0,263 (40.2)
NCT03548935,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,Semaglutide,treatment,1306,0,0.0,126.0,14.0,126±14
NCT03548935,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,Placebo,control,655,0,0.0,127.0,14.0,127±14
NCT03548935,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Semaglutide,treatment,1306,0,0.0,80.0,10.0,80±10
NCT03548935,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Placebo,control,655,0,0.0,80.0,10.0,80±10
NCT03548935,Pulse,Pulse — beats/min,,continuous,beats/min,Semaglutide,treatment,1306,0,0.0,72.0,10.0,72±10
NCT03548935,Pulse,Pulse — beats/min,,continuous,beats/min,Placebo,control,655,0,0.0,72.0,10.0,72±10
NCT03548935,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,189.6,20.5,189.6 (20.5)
NCT03548935,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,192.1,19.4,192.1 (19.4)
NCT03548935,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,49.4,25.6,49.4 (25.6)
NCT03548935,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,49.5,25.0,49.5 (25.0)
NCT03548935,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,110.3,31.6,110.3 (31.6)
NCT03548935,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,112.5,29.8,112.5 (29.8)
NCT03548935,VLDL cholesterol,VLDL cholesterol,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,24.5,45.8,24.5 (45.8)
NCT03548935,VLDL cholesterol,VLDL cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,24.9,46.5,24.9 (46.5)
NCT03548935,Free fatty acids,Free fatty acids,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,12.3,57.9,12.3 (57.9)
NCT03548935,Free fatty acids,Free fatty acids,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,12.7,53.8,12.7 (53.8)
NCT03548935,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,Semaglutide,treatment,1306,0,0.0,126.2,47.4,126.2 (47.4)
NCT03548935,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,Placebo,control,655,0,0.0,127.9,49.0,127.9 (49.0)
NCT03548935,Estimated glomerular filtration rate,Estimated glomerular filtration rate — geometric mean ml/min/1.73 m2 (coefficient of variation)‖,,continuous,ml/min/1.73 m2,Semaglutide,treatment,1306,0,0.0,96.3,18.7,96.3 (18.7)
NCT03548935,Estimated glomerular filtration rate,Estimated glomerular filtration rate — geometric mean ml/min/1.73 m2 (coefficient of variation)‖,,continuous,ml/min/1.73 m2,Placebo,control,655,0,0.0,95.9,18.3,95.9 (18.3)
NCT03548935,Dyslipidemia,Dyslipidemia — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,499,38.2,0.0,0.0,499 (38.2)
NCT03548935,Dyslipidemia,Dyslipidemia — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,226,34.5,0.0,0.0,226 (34.5)
NCT03548935,Hypertension,Hypertension — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,472,36.1,0.0,0.0,472 (36.1)
NCT03548935,Hypertension,Hypertension — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,234,35.7,0.0,0.0,234 (35.7)
NCT03548935,Knee osteoarthritis,Knee osteoarthritis — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,173,13.2,0.0,0.0,173 (13.2)
NCT03548935,Knee osteoarthritis,Knee osteoarthritis — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,102,15.6,0.0,0.0,102 (15.6)
NCT03548935,Obstructive sleep apnea,Obstructive sleep apnea — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,159,12.2,0.0,0.0,159 (12.2)
NCT03548935,Obstructive sleep apnea,Obstructive sleep apnea — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,71,10.8,0.0,0.0,71 (10.8)
NCT03548935,Asthma or chronic obstructive pulmonary disease,Asthma or chronic obstructive pulmonary disease — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,147,11.3,0.0,0.0,147 (11.3)
NCT03548935,Asthma or chronic obstructive pulmonary disease,Asthma or chronic obstructive pulmonary disease — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,80,12.2,0.0,0.0,80 (12.2)
NCT03548935,Nonalcoholic fatty liver disease,Nonalcoholic fatty liver disease — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,101,7.7,0.0,0.0,101 (7.7)
NCT03548935,Nonalcoholic fatty liver disease,Nonalcoholic fatty liver disease — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,62,9.5,0.0,0.0,62 (9.5)
NCT03548935,Polycystic ovarian syndrome,Polycystic ovarian syndrome — no./total no. (%)††,Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,955,62,6.5,0.0,0.0,62/955 (6.5)
NCT03548935,Polycystic ovarian syndrome,Polycystic ovarian syndrome — no./total no. (%)††,Coexisting conditions at the time of screening,categorical,,Placebo,control,498,34,6.8,0.0,0.0,34/498 (6.8)
NCT03548935,Coronary artery disease,Coronary artery disease — no. (%),Coexisting conditions at the time of screening,categorical,,Semaglutide,treatment,1306,32,2.5,0.0,0.0,32 (2.5)
NCT03548935,Coronary artery disease,Coronary artery disease — no. (%),Coexisting conditions at the time of screening,categorical,,Placebo,control,655,17,2.6,0.0,0.0,17 (2.6)
NCT03548935,No. of coexisting conditions at screening,None,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,328,25.1,0.0,0.0,328 (25.1)
NCT03548935,No. of coexisting conditions at screening,None,No. of coexisting conditions at screening,categorical,,Placebo,control,655,163,24.9,0.0,0.0,163 (24.9)
NCT03548935,No. of coexisting conditions at screening,1,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,337,25.8,0.0,0.0,337 (25.8)
NCT03548935,No. of coexisting conditions at screening,1,No. of coexisting conditions at screening,categorical,,Placebo,control,655,187,28.5,0.0,0.0,187 (28.5)
NCT03548935,No. of coexisting conditions at screening,2,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,298,22.8,0.0,0.0,298 (22.8)
NCT03548935,No. of coexisting conditions at screening,2,No. of coexisting conditions at screening,categorical,,Placebo,control,655,135,20.6,0.0,0.0,135 (20.6)
NCT03548935,No. of coexisting conditions at screening,3,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,183,14.0,0.0,0.0,183 (14.0)
NCT03548935,No. of coexisting conditions at screening,3,No. of coexisting conditions at screening,categorical,,Placebo,control,655,96,14.7,0.0,0.0,96 (14.7)
NCT03548935,No. of coexisting conditions at screening,4,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,96,7.4,0.0,0.0,96 (7.4)
NCT03548935,No. of coexisting conditions at screening,4,No. of coexisting conditions at screening,categorical,,Placebo,control,655,43,6.6,0.0,0.0,43 (6.6)
NCT03548935,No. of coexisting conditions at screening,≥5,No. of coexisting conditions at screening,categorical,,Semaglutide,treatment,1306,64,4.9,0.0,0.0,64 (4.9)
NCT03548935,No. of coexisting conditions at screening,≥5,No. of coexisting conditions at screening,categorical,,Placebo,control,655,31,4.7,0.0,0.0,31 (4.7)
NCT03548935,SF-36,Physical functioning score,SF-36‡‡,continuous,,Semaglutide,treatment,1306,0,0.0,51.0,6.9,51.0±6.9
NCT03548935,SF-36,Physical functioning score,SF-36‡‡,continuous,,Placebo,control,655,0,0.0,50.8,7.9,50.8±7.9
NCT03548935,SF-36,Physical component summary score,SF-36‡‡,continuous,,Semaglutide,treatment,1306,0,0.0,51.1,7.3,51.1±7.3
NCT03548935,SF-36,Physical component summary score,SF-36‡‡,continuous,,Placebo,control,655,0,0.0,51.1,7.9,51.1±7.9
NCT03548935,SF-36,Mental component summary score,SF-36‡‡,continuous,,Semaglutide,treatment,1306,0,0.0,55.4,5.7,55.4±5.7
NCT03548935,SF-36,Mental component summary score,SF-36‡‡,continuous,,Placebo,control,655,0,0.0,55.5,5.9,55.5±5.9
NCT03548935,IWQOL-Lite-CT,Physical function score,IWQOL-Lite-CT§§,continuous,,Semaglutide,treatment,1306,0,0.0,65.4,24.0,65.4±24.0
NCT03548935,IWQOL-Lite-CT,Physical function score,IWQOL-Lite-CT§§,continuous,,Placebo,control,655,0,0.0,64.0,24.4,64.0±24.4
NCT03548935,IWQOL-Lite-CT,Total score,IWQOL-Lite-CT§§,continuous,,Semaglutide,treatment,1306,0,0.0,63.6,21.2,63.6±21.2
NCT03548935,IWQOL-Lite-CT,Total score,IWQOL-Lite-CT§§,continuous,,Placebo,control,655,0,0.0,63.3,20.9,63.3±20.9
NCT00849017,Age,Age (years),,continuous,years,Placebo,control,101,0,0.0,53.1,11.7,53.1±11.7
NCT00849017,Age,Age (years),,continuous,years,Albiglutide 30 mg weekly,treatment,101,0,0.0,53.6,10.9,53.6±10.9
NCT00849017,Age,Age (years),,continuous,years,Albiglutide 50 mg weekly,treatment,99,0,0.0,52.0,11.8,52.0±11.8
NCT00849017,Sex,"Sex, male",Sex,categorical,,Placebo,control,101,58,57.4,0.0,0.0,58 (57.4)
NCT00849017,Sex,"Sex, male",Sex,categorical,,Albiglutide 30 mg weekly,treatment,101,58,57.4,0.0,0.0,58 (57.4)
NCT00849017,Sex,"Sex, male",Sex,categorical,,Albiglutide 50 mg weekly,treatment,99,50,50.5,0.0,0.0,50 (50.5)
NCT00849017,Weight,Weight (kg),,continuous,kg,Placebo,control,101,0,0.0,95.4,19.9,95.4±19.9
NCT00849017,Weight,Weight (kg),,continuous,kg,Albiglutide 30 mg weekly,treatment,101,0,0.0,95.8,19.6,95.8±19.6
NCT00849017,Weight,Weight (kg),,continuous,kg,Albiglutide 50 mg weekly,treatment,99,0,0.0,97.1,17.8,97.10±17.8
NCT00849017,BMI,BMI (kg/m2),,continuous,kg/m2,Placebo,control,101,0,0.0,33.0,5.4,33.00±5.4
NCT00849017,BMI,BMI (kg/m2),,continuous,kg/m2,Albiglutide 30 mg weekly,treatment,101,0,0.0,33.7,5.1,33.7±5.1
NCT00849017,BMI,BMI (kg/m2),,continuous,kg/m2,Albiglutide 50 mg weekly,treatment,99,0,0.0,33.9,5.5,33.9±5.5
NCT00849017,Baseline HbA1c,Baseline HbA1c (%),,continuous,%,Placebo,control,101,0,0.0,8.0,0.9,8.0±0.9
NCT00849017,Baseline HbA1c,Baseline HbA1c (%),,continuous,%,Albiglutide 30 mg weekly,treatment,101,0,0.0,8.0,0.8,8.0±0.8
NCT00849017,Baseline HbA1c,Baseline HbA1c (%),,continuous,%,Albiglutide 50 mg weekly,treatment,99,0,0.0,8.2,0.9,8.2±0.9
NCT00849017,Baseline HbA1c,Baseline HbA1c (mmol/mol),,continuous,mmol/mol,Placebo,control,101,0,0.0,64.2,9.9,64.2±9.9
NCT00849017,Baseline HbA1c,Baseline HbA1c (mmol/mol),,continuous,mmol/mol,Albiglutide 30 mg weekly,treatment,101,0,0.0,64.5,9.5,64.5±9.5
NCT00849017,Baseline HbA1c,Baseline HbA1c (mmol/mol),,continuous,mmol/mol,Albiglutide 50 mg weekly,treatment,99,0,0.0,66.2,10.3,66.2±10.3
NCT00849017,Duration of diabetes,Duration of diabetes (years),,continuous,years,Placebo,control,101,0,0.0,4.3,4.0,4.3±4.0
NCT00849017,Duration of diabetes,Duration of diabetes (years),,continuous,years,Albiglutide 30 mg weekly,treatment,101,0,0.0,3.4,3.7,3.4±3.7
NCT00849017,Duration of diabetes,Duration of diabetes (years),,continuous,years,Albiglutide 50 mg weekly,treatment,99,0,0.0,4.2,4.6,4.2±4.6
NCT00849017,Prior MI,Prior MI,,categorical,,Placebo,control,101,4,4.0,0.0,0.0,4 (4.0)
NCT00849017,Prior MI,Prior MI,,categorical,,Albiglutide 30 mg weekly,treatment,101,3,3.0,0.0,0.0,3 (3.0)
NCT00849017,Prior MI,Prior MI,,categorical,,Albiglutide 50 mg weekly,treatment,99,2,2.0,0.0,0.0,2 (2.0)
NCT00849017,Race,White,Race,categorical,,Placebo,control,101,79,78.2,0.0,0.0,79 (78.2)
NCT00849017,Race,White,Race,categorical,,Albiglutide 30 mg weekly,treatment,101,85,84.2,0.0,0.0,85 (84.2)
NCT00849017,Race,White,Race,categorical,,Albiglutide 50 mg weekly,treatment,99,78,78.8,0.0,0.0,78 (78.8)
NCT00849017,Race,African-American/African,Race,categorical,,Placebo,control,101,14,13.9,0.0,0.0,14 (13.9)
NCT00849017,Race,African-American/African,Race,categorical,,Albiglutide 30 mg weekly,treatment,101,10,9.9,0.0,0.0,10 (9.9)
NCT00849017,Race,African-American/African,Race,categorical,,Albiglutide 50 mg weekly,treatment,99,14,14.1,0.0,0.0,14 (14.1)
NCT00849017,Race,Asian,Race,categorical,,Placebo,control,101,5,5.0,0.0,0.0,5 (5.0)
NCT00849017,Race,Asian,Race,categorical,,Albiglutide 30 mg weekly,treatment,101,1,1.0,0.0,0.0,1 (1.0)
NCT00849017,Race,Asian,Race,categorical,,Albiglutide 50 mg weekly,treatment,99,1,1.0,0.0,0.0,1 (1.0)
NCT00849017,Ethnicity,Ethnicity Hispanic/Latino,Ethnicity,categorical,,Placebo,control,101,29,28.7,0.0,0.0,29 (28.7)
NCT00849017,Ethnicity,Ethnicity Hispanic/Latino,Ethnicity,categorical,,Albiglutide 30 mg weekly,treatment,101,30,29.7,0.0,0.0,30 (29.7)
NCT00849017,Ethnicity,Ethnicity Hispanic/Latino,Ethnicity,categorical,,Albiglutide 50 mg weekly,treatment,99,26,26.3,0.0,0.0,26 (26.3)
NCT05567796,Age,Age — yr,,continuous,years,Cagrilintide-Semaglutide,treatment,2108,0,0.0,47.1,11.9,47.1±11.9
NCT05567796,Age,Age — yr,,continuous,years,Semaglutide,treatment,302,0,0.0,47.4,11.5,47.4±11.5
NCT05567796,Age,Age — yr,,continuous,years,Cagrilintide,treatment,302,0,0.0,46.6,11.2,46.6±11.2
NCT05567796,Age,Age — yr,,continuous,years,Placebo,control,705,0,0.0,46.7,11.9,46.7±11.9
NCT05567796,Female sex,Female sex — no. (%),,categorical,,Cagrilintide-Semaglutide,treatment,2108,1441,68.4,0.0,0.0,1441 (68.4)
NCT05567796,Female sex,Female sex — no. (%),,categorical,,Semaglutide,treatment,302,199,65.9,0.0,0.0,199 (65.9)
NCT05567796,Female sex,Female sex — no. (%),,categorical,,Cagrilintide,treatment,302,208,68.9,0.0,0.0,208 (68.9)
NCT05567796,Female sex,Female sex — no. (%),,categorical,,Placebo,control,705,461,65.4,0.0,0.0,461 (65.4)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),White,categorical,,Cagrilintide-Semaglutide,treatment,2108,1513,71.8,0.0,0.0,1513 (71.8)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),White,categorical,,Semaglutide,treatment,302,233,77.2,0.0,0.0,233 (77.2)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),White,categorical,,Cagrilintide,treatment,302,224,74.2,0.0,0.0,224 (74.2)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),White,categorical,,Placebo,control,705,489,69.4,0.0,0.0,489 (69.4)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Asian,categorical,,Cagrilintide-Semaglutide,treatment,2108,386,18.3,0.0,0.0,386 (18.3)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Asian,categorical,,Semaglutide,treatment,302,44,14.6,0.0,0.0,44 (14.6)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Asian,categorical,,Cagrilintide,treatment,302,52,17.2,0.0,0.0,52 (17.2)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Asian,categorical,,Placebo,control,705,149,21.1,0.0,0.0,149 (21.1)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Black or African American,categorical,,Cagrilintide-Semaglutide,treatment,2108,116,5.5,0.0,0.0,116 (5.5)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Black or African American,categorical,,Semaglutide,treatment,302,16,5.3,0.0,0.0,16 (5.3)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Black or African American,categorical,,Cagrilintide,treatment,302,15,5.0,0.0,0.0,15 (5.0)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Black or African American,categorical,,Placebo,control,705,42,6.0,0.0,0.0,42 (6.0)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Other,categorical,,Cagrilintide-Semaglutide,treatment,2108,93,4.4,0.0,0.0,93 (4.4)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Other,categorical,,Semaglutide,treatment,302,9,3.0,0.0,0.0,9 (3.0)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Other,categorical,,Cagrilintide,treatment,302,11,3.6,0.0,0.0,11 (3.6)
NCT05567796,Race or ethnic group,Race or ethnic group — no. (%),Other,categorical,,Placebo,control,705,25,3.5,0.0,0.0,25 (3.5)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Yes,categorical,,Cagrilintide-Semaglutide,treatment,2108,244,11.6,0.0,0.0,244 (11.6)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Yes,categorical,,Semaglutide,treatment,302,33,10.9,0.0,0.0,33 (10.9)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Yes,categorical,,Cagrilintide,treatment,302,24,7.9,0.0,0.0,24 (7.9)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Yes,categorical,,Placebo,control,705,71,10.1,0.0,0.0,71 (10.1)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),No,categorical,,Cagrilintide-Semaglutide,treatment,2108,1787,84.8,0.0,0.0,1787 (84.8)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),No,categorical,,Semaglutide,treatment,302,263,87.1,0.0,0.0,263 (87.1)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),No,categorical,,Cagrilintide,treatment,302,265,87.7,0.0,0.0,265 (87.7)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),No,categorical,,Placebo,control,705,614,87.1,0.0,0.0,614 (87.1)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Not reported,categorical,,Cagrilintide-Semaglutide,treatment,2108,77,3.7,0.0,0.0,77 (3.7)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Not reported,categorical,,Semaglutide,treatment,302,6,2.0,0.0,0.0,6 (2.0)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Not reported,categorical,,Cagrilintide,treatment,302,13,4.3,0.0,0.0,13 (4.3)
NCT05567796,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group — no. (%),Not reported,categorical,,Placebo,control,705,20,2.8,0.0,0.0,20 (2.8)
NCT05567796,Body weight,Body weight — kg,,continuous,kg,Cagrilintide-Semaglutide,treatment,2108,0,0.0,107.2,23.2,107.2±23.2
NCT05567796,Body weight,Body weight — kg,,continuous,kg,Semaglutide,treatment,302,0,0.0,105.9,20.7,105.9±20.7
NCT05567796,Body weight,Body weight — kg,,continuous,kg,Cagrilintide,treatment,302,0,0.0,106.5,22.9,106.5±22.9
NCT05567796,Body weight,Body weight — kg,,continuous,kg,Placebo,control,705,0,0.0,106.6,23.7,106.6±23.7
NCT05567796,BMI,BMI,Mean,continuous,,Cagrilintide-Semaglutide,treatment,2108,0,0.0,38.0,6.8,38.0±6.8
NCT05567796,BMI,BMI,Mean,continuous,,Semaglutide,treatment,302,0,0.0,37.4,5.9,37.4±5.9
NCT05567796,BMI,BMI,Mean,continuous,,Cagrilintide,treatment,302,0,0.0,38.0,6.4,38.0±6.4
NCT05567796,BMI,BMI,Mean,continuous,,Placebo,control,705,0,0.0,37.8,7.1,37.8±7.1
NCT05567796,BMI,BMI,<30,categorical,,Cagrilintide-Semaglutide,treatment,2108,126,6.0,0.0,0.0,126 (6.0)
NCT05567796,BMI,BMI,<30,categorical,,Semaglutide,treatment,302,20,6.6,0.0,0.0,20 (6.6)
NCT05567796,BMI,BMI,<30,categorical,,Cagrilintide,treatment,302,13,4.3,0.0,0.0,13 (4.3)
NCT05567796,BMI,BMI,<30,categorical,,Placebo,control,705,49,7.0,0.0,0.0,49 (7.0)
NCT05567796,BMI,BMI,30 to <35,categorical,,Cagrilintide-Semaglutide,treatment,2108,680,32.3,0.0,0.0,680 (32.3)
NCT05567796,BMI,BMI,30 to <35,categorical,,Semaglutide,treatment,302,101,33.4,0.0,0.0,101 (33.4)
NCT05567796,BMI,BMI,30 to <35,categorical,,Cagrilintide,treatment,302,102,33.8,0.0,0.0,102 (33.8)
NCT05567796,BMI,BMI,30 to <35,categorical,,Placebo,control,705,225,31.9,0.0,0.0,225 (31.9)
NCT05567796,BMI,BMI,35 to <40,categorical,,Cagrilintide-Semaglutide,treatment,2108,628,29.8,0.0,0.0,628 (29.8)
NCT05567796,BMI,BMI,35 to <40,categorical,,Semaglutide,treatment,302,94,31.1,0.0,0.0,94 (31.1)
NCT05567796,BMI,BMI,35 to <40,categorical,,Cagrilintide,treatment,302,95,31.5,0.0,0.0,95 (31.5)
NCT05567796,BMI,BMI,35 to <40,categorical,,Placebo,control,705,208,29.5,0.0,0.0,208 (29.5)
NCT05567796,BMI,BMI,≥40,categorical,,Cagrilintide-Semaglutide,treatment,2108,674,32.0,0.0,0.0,674 (32.0)
NCT05567796,BMI,BMI,≥40,categorical,,Semaglutide,treatment,302,87,28.8,0.0,0.0,87 (28.8)
NCT05567796,BMI,BMI,≥40,categorical,,Cagrilintide,treatment,302,92,30.5,0.0,0.0,92 (30.5)
NCT05567796,BMI,BMI,≥40,categorical,,Placebo,control,705,223,31.6,0.0,0.0,223 (31.6)
NCT05567796,Waist circumference,Waist circumference — cm,,continuous,cm,Cagrilintide-Semaglutide,treatment,2108,0,0.0,115.0,15.7,115.0±15.7
NCT05567796,Waist circumference,Waist circumference — cm,,continuous,cm,Semaglutide,treatment,302,0,0.0,114.2,15.3,114.2±15.3
NCT05567796,Waist circumference,Waist circumference — cm,,continuous,cm,Cagrilintide,treatment,302,0,0.0,114.1,14.9,114.1±14.9
NCT05567796,Waist circumference,Waist circumference — cm,,continuous,cm,Placebo,control,705,0,0.0,114.1,15.3,114.1±15.3
NCT05567796,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Cagrilintide-Semaglutide,treatment,2108,0,0.0,5.5,0.4,5.5±0.4
NCT05567796,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Semaglutide,treatment,302,0,0.0,5.5,0.4,5.5±0.4
NCT05567796,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Cagrilintide,treatment,302,0,0.0,5.5,0.4,5.5±0.4
NCT05567796,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Placebo,control,705,0,0.0,5.5,0.4,5.5±0.4
NCT05567796,Fasting plasma glucose,Fasting plasma glucose — mg/dl,,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,98.6,11.8,98.6±11.8
NCT05567796,Fasting plasma glucose,Fasting plasma glucose — mg/dl,,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,98.2,11.9,98.2±11.9
NCT05567796,Fasting plasma glucose,Fasting plasma glucose — mg/dl,,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,99.8,11.2,99.8±11.2
NCT05567796,Fasting plasma glucose,Fasting plasma glucose — mg/dl,,continuous,mg/dl,Placebo,control,705,0,0.0,99.4,12.6,99.4±12.6
NCT05567796,Fasting serum insulin,Fasting serum insulin — pmol/liter,,continuous,pmol/liter,Cagrilintide-Semaglutide,treatment,2108,0,0.0,103.5,70.3,103.5±70.3
NCT05567796,Fasting serum insulin,Fasting serum insulin — pmol/liter,,continuous,pmol/liter,Semaglutide,treatment,302,0,0.0,105.7,68.1,105.7±68.1
NCT05567796,Fasting serum insulin,Fasting serum insulin — pmol/liter,,continuous,pmol/liter,Cagrilintide,treatment,302,0,0.0,104.1,67.1,104.1±67.1
NCT05567796,Fasting serum insulin,Fasting serum insulin — pmol/liter,,continuous,pmol/liter,Placebo,control,705,0,0.0,104.7,72.3,104.7±72.3
NCT05567796,Systolic blood pressure,Systolic blood pressure — mm Hg,,continuous,mm Hg,Cagrilintide-Semaglutide,treatment,2108,0,0.0,126.8,14.1,126.8±14.1
NCT05567796,Systolic blood pressure,Systolic blood pressure — mm Hg,,continuous,mm Hg,Semaglutide,treatment,302,0,0.0,127.0,14.8,127.0±14.8
NCT05567796,Systolic blood pressure,Systolic blood pressure — mm Hg,,continuous,mm Hg,Cagrilintide,treatment,302,0,0.0,126.9,13.4,126.9±13.4
NCT05567796,Systolic blood pressure,Systolic blood pressure — mm Hg,,continuous,mm Hg,Placebo,control,705,0,0.0,128.1,14.7,128.1±14.7
NCT05567796,Diastolic blood pressure,Diastolic blood pressure — mm Hg,,continuous,mm Hg,Cagrilintide-Semaglutide,treatment,2108,0,0.0,82.0,9.2,82.0±9.2
NCT05567796,Diastolic blood pressure,Diastolic blood pressure — mm Hg,,continuous,mm Hg,Semaglutide,treatment,302,0,0.0,81.8,9.4,81.8±9.4
NCT05567796,Diastolic blood pressure,Diastolic blood pressure — mm Hg,,continuous,mm Hg,Cagrilintide,treatment,302,0,0.0,81.8,9.1,81.8±9.1
NCT05567796,Diastolic blood pressure,Diastolic blood pressure — mm Hg,,continuous,mm Hg,Placebo,control,705,0,0.0,82.5,9.2,82.5±9.2
NCT05567796,Total cholesterol,Total cholesterol,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,190.0,20.2,190.0±20.2
NCT05567796,Total cholesterol,Total cholesterol,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,186.7,20.0,186.7±20.0
NCT05567796,Total cholesterol,Total cholesterol,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,194.4,19.7,194.4±19.7
NCT05567796,Total cholesterol,Total cholesterol,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,190.0,20.1,190.0±20.1
NCT05567796,HDL cholesterol,HDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,48.7,24.7,48.7±24.7
NCT05567796,HDL cholesterol,HDL cholesterol,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,48.8,26.6,48.8±26.6
NCT05567796,HDL cholesterol,HDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,48.4,24.4,48.4±24.4
NCT05567796,HDL cholesterol,HDL cholesterol,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,48.9,25.4,48.9±25.4
NCT05567796,LDL cholesterol,LDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,112.1,29.9,112.1±29.9
NCT05567796,LDL cholesterol,LDL cholesterol,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,107.0,34.5,107.0±34.5
NCT05567796,LDL cholesterol,LDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,115.8,30.3,115.8±30.3
NCT05567796,LDL cholesterol,LDL cholesterol,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,111.1,29.9,111.1±29.9
NCT05567796,Non-HDL cholesterol,Non-HDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,138.8,27.1,138.8±27.1
NCT05567796,Non-HDL cholesterol,Non-HDL cholesterol,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,135.4,26.8,135.4±26.8
NCT05567796,Non-HDL cholesterol,Non-HDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,143.2,26.5,143.2±26.5
NCT05567796,Non-HDL cholesterol,Non-HDL cholesterol,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,138.4,26.8,138.4±26.8
NCT05567796,VLDL cholesterol,VLDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,24.0,49.3,24.0±49.3
NCT05567796,VLDL cholesterol,VLDL cholesterol,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,24.2,51.4,24.2±51.4
NCT05567796,VLDL cholesterol,VLDL cholesterol,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,24.2,50.3,24.2±50.3
NCT05567796,VLDL cholesterol,VLDL cholesterol,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,24.2,51.1,24.2±51.1
NCT05567796,Free fatty acids,Free fatty acids,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,13.5,48.1,13.5±48.1
NCT05567796,Free fatty acids,Free fatty acids,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,13.3,46.5,13.3±46.5
NCT05567796,Free fatty acids,Free fatty acids,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,13.3,46.0,13.3±46.0
NCT05567796,Free fatty acids,Free fatty acids,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,13.6,46.8,13.6±46.8
NCT05567796,Triglycerides,Triglycerides,Lipids,continuous,mg/dl,Cagrilintide-Semaglutide,treatment,2108,0,0.0,120.7,49.6,120.7±49.6
NCT05567796,Triglycerides,Triglycerides,Lipids,continuous,mg/dl,Semaglutide,treatment,302,0,0.0,121.8,53.5,121.8±53.5
NCT05567796,Triglycerides,Triglycerides,Lipids,continuous,mg/dl,Cagrilintide,treatment,302,0,0.0,121.7,51.0,121.7±51.0
NCT05567796,Triglycerides,Triglycerides,Lipids,continuous,mg/dl,Placebo,control,705,0,0.0,122.3,52.2,122.3±52.2
NCT05567796,C-reactive protein,C-reactive protein — mg/liter,,continuous,mg/liter,Cagrilintide-Semaglutide,treatment,2108,0,0.0,3.2,151.9,3.2±151.9
NCT05567796,C-reactive protein,C-reactive protein — mg/liter,,continuous,mg/liter,Semaglutide,treatment,302,0,0.0,3.2,142.9,3.2±142.9
NCT05567796,C-reactive protein,C-reactive protein — mg/liter,,continuous,mg/liter,Cagrilintide,treatment,302,0,0.0,3.0,140.8,3.0±140.8
NCT05567796,C-reactive protein,C-reactive protein — mg/liter,,continuous,mg/liter,Placebo,control,705,0,0.0,3.0,148.4,3.0±148.4
NCT05567796,SF-36 Physical Functioning score,SF-36 Physical Functioning score,Physical function,continuous,,Cagrilintide-Semaglutide,treatment,2108,0,0.0,45.7,8.9,45.7±8.9
NCT05567796,SF-36 Physical Functioning score,SF-36 Physical Functioning score,Physical function,continuous,,Semaglutide,treatment,302,0,0.0,46.6,8.6,46.6±8.6
NCT05567796,SF-36 Physical Functioning score,SF-36 Physical Functioning score,Physical function,continuous,,Cagrilintide,treatment,302,0,0.0,46.7,8.1,46.7±8.1
NCT05567796,SF-36 Physical Functioning score,SF-36 Physical Functioning score,Physical function,continuous,,Placebo,control,705,0,0.0,45.7,8.9,45.7±8.9
NCT05567796,SF-36 Physical Functioning score in participants with poor physical function,SF-36 Physical Functioning score in participants with poor physical function,Physical function,continuous,,Cagrilintide-Semaglutide,treatment,2108,0,0.0,39.3,10.3,39.3±10.3
NCT05567796,SF-36 Physical Functioning score in participants with poor physical function,SF-36 Physical Functioning score in participants with poor physical function,Physical function,continuous,,Semaglutide,treatment,302,0,0.0,40.6,9.4,40.6±9.4
NCT05567796,SF-36 Physical Functioning score in participants with poor physical function,SF-36 Physical Functioning score in participants with poor physical function,Physical function,continuous,,Cagrilintide,treatment,302,0,0.0,42.6,10.3,42.6±10.3
NCT05567796,SF-36 Physical Functioning score in participants with poor physical function,SF-36 Physical Functioning score in participants with poor physical function,Physical function,continuous,,Placebo,control,705,0,0.0,39.9,10.0,39.9±10.0
NCT05567796,IWQOL-Lite-CT Physical Function score,IWQOL-Lite-CT Physical Function score,Physical function,continuous,,Cagrilintide-Semaglutide,treatment,2108,0,0.0,54.0,23.3,54.0±23.3
NCT05567796,IWQOL-Lite-CT Physical Function score,IWQOL-Lite-CT Physical Function score,Physical function,continuous,,Semaglutide,treatment,302,0,0.0,55.2,22.4,55.2±22.4
NCT05567796,IWQOL-Lite-CT Physical Function score,IWQOL-Lite-CT Physical Function score,Physical function,continuous,,Cagrilintide,treatment,302,0,0.0,55.9,22.9,55.9±22.9
NCT05567796,IWQOL-Lite-CT Physical Function score,IWQOL-Lite-CT Physical Function score,Physical function,continuous,,Placebo,control,705,0,0.0,54.7,23.8,54.7±23.8
NCT05567796,IWQOL-Lite-CT Physical Function score in participants with poor physical function,IWQOL-Lite-CT Physical Function score in participants with poor physical function,Physical function,continuous,,Cagrilintide-Semaglutide,treatment,2108,0,0.0,36.7,22.4,36.7±22.4
NCT05567796,IWQOL-Lite-CT Physical Function score in participants with poor physical function,IWQOL-Lite-CT Physical Function score in participants with poor physical function,Physical function,continuous,,Semaglutide,treatment,302,0,0.0,37.1,18.3,37.1±18.3
NCT05567796,IWQOL-Lite-CT Physical Function score in participants with poor physical function,IWQOL-Lite-CT Physical Function score in participants with poor physical function,Physical function,continuous,,Cagrilintide,treatment,302,0,0.0,41.3,23.9,41.3±23.9
NCT05567796,IWQOL-Lite-CT Physical Function score in participants with poor physical function,IWQOL-Lite-CT Physical Function score in participants with poor physical function,Physical function,continuous,,Placebo,control,705,0,0.0,37.1,23.0,37.1±23.0
NCT04707469,Age,"Age, years",,continuous,years,Oral semaglutide 14 mg group,treatment,536,0,0.0,58.4,10.4,58·4 (10·4)
NCT04707469,Age,"Age, years",,continuous,years,Oral semaglutide 25 mg group,treatment,535,0,0.0,58.8,10.7,58·8 (10·7)
NCT04707469,Age,"Age, years",,continuous,years,Oral semaglutide 50 mg group,treatment,535,0,0.0,57.6,11.2,57·6 (11·2)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 14 mg group,treatment,536,211,39.0,0.0,0.0,211 (39%)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 25 mg group,treatment,535,231,43.0,0.0,0.0,231 (43%)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 50 mg group,treatment,535,228,43.0,0.0,0.0,228 (43%)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 14 mg group,treatment,536,325,61.0,0.0,0.0,325 (61%)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 25 mg group,treatment,535,304,57.0,0.0,0.0,304 (57%)
NCT04707469,Sex,Sex,Sex,categorical,,Oral semaglutide 50 mg group,treatment,535,307,57.0,0.0,0.0,307 (57%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,424,79.0,0.0,0.0,424 (79%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,432,81.0,0.0,0.0,432 (81%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,398,74.0,0.0,0.0,398 (74%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,85,16.0,0.0,0.0,85 (16%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,73,14.0,0.0,0.0,73 (14%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,111,21.0,0.0,0.0,111 (21%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,19,4.0,0.0,0.0,19 (4%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,22,4.0,0.0,0.0,22 (4%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,18,3.0,0.0,0.0,18 (3%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,1,0.0,0.0,0.0,1 (<1%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,0,0.0,0.0,0.0,0
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,0,0.0,0.0,0.0,0
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,0,0.0,0.0,0.0,0
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,2,0.0,0.0,0.0,2 (<1%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,0,0.0,0.0,0.0,0
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 14 mg group,treatment,536,7,1.0,0.0,0.0,7 (1%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 25 mg group,treatment,535,6,1.0,0.0,0.0,6 (1%)
NCT04707469,Race,Race,Race,categorical,,Oral semaglutide 50 mg group,treatment,535,8,1.0,0.0,0.0,8 (1%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 14 mg group,treatment,536,38,7.0,0.0,0.0,38 (7%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 25 mg group,treatment,535,37,7.0,0.0,0.0,37 (7%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 50 mg group,treatment,535,36,7.0,0.0,0.0,36 (7%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 14 mg group,treatment,536,498,93.0,0.0,0.0,498 (93%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 25 mg group,treatment,535,498,93.0,0.0,0.0,498 (93%)
NCT04707469,Ethnicity,Ethnicity,Ethnicity,categorical,,Oral semaglutide 50 mg group,treatment,535,499,93.0,0.0,0.0,499 (93%)
NCT04707469,Duration of diabetes,"Duration of diabetes, years",,continuous,years,Oral semaglutide 14 mg group,treatment,536,0,0.0,9.4,5.9,9·4 (5·9)
NCT04707469,Duration of diabetes,"Duration of diabetes, years",,continuous,years,Oral semaglutide 25 mg group,treatment,535,0,0.0,9.7,6.7,9·7 (6·7)
NCT04707469,Duration of diabetes,"Duration of diabetes, years",,continuous,years,Oral semaglutide 50 mg group,treatment,535,0,0.0,8.9,5.9,8·9 (5·9)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,mmol/mol,Oral semaglutide 14 mg group,treatment,536,0,0.0,74.2,8.5,74·2 (8·5)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,mmol/mol,Oral semaglutide 25 mg group,treatment,535,0,0.0,74.6,8.2,74·6 (8·2)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,mmol/mol,Oral semaglutide 50 mg group,treatment,535,0,0.0,74.3,8.2,74·3 (8·2)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,%,Oral semaglutide 14 mg group,treatment,536,0,0.0,8.9,0.8,8·9 (0·8)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,%,Oral semaglutide 25 mg group,treatment,535,0,0.0,9.0,0.8,9·0 (0·8)
NCT04707469,HbA1c,HbA1c,HbA1c,continuous,%,Oral semaglutide 50 mg group,treatment,535,0,0.0,8.9,0.7,8·9 (0·7)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mmol/L,Oral semaglutide 14 mg group,treatment,532,0,0.0,10.8,2.9,10·8 (2·9)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mmol/L,Oral semaglutide 25 mg group,treatment,526,0,0.0,11.0,3.1,11·0 (3·1)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mmol/L,Oral semaglutide 50 mg group,treatment,530,0,0.0,10.8,2.9,10·8 (2·9)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mg/dL,Oral semaglutide 14 mg group,treatment,532,0,0.0,195.1,52.8,195·1 (52·8)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mg/dL,Oral semaglutide 25 mg group,treatment,526,0,0.0,198.0,55.4,198·0 (55·4)
NCT04707469,Fasting plasma glucose,Fasting plasma glucose*,Fasting plasma glucose,continuous,mg/dL,Oral semaglutide 50 mg group,treatment,530,0,0.0,195.5,51.7,195·5 (51·7)
NCT04707469,Bodyweight,"Bodyweight, kg",,continuous,kg,Oral semaglutide 14 mg group,treatment,536,0,0.0,96.4,20.8,96·4 (20·8)
NCT04707469,Bodyweight,"Bodyweight, kg",,continuous,kg,Oral semaglutide 25 mg group,treatment,535,0,0.0,96.6,21.2,96·6 (21·2)
NCT04707469,Bodyweight,"Bodyweight, kg",,continuous,kg,Oral semaglutide 50 mg group,treatment,535,0,0.0,96.1,22.8,96·1 (22·8)
NCT04707469,BMI,"BMI, kg/m2",,continuous,kg/m2,Oral semaglutide 14 mg group,treatment,536,0,0.0,33.7,6.1,33·7 (6·1)
NCT04707469,BMI,"BMI, kg/m2",,continuous,kg/m2,Oral semaglutide 25 mg group,treatment,535,0,0.0,34.1,6.5,34·1 (6·5)
NCT04707469,BMI,"BMI, kg/m2",,continuous,kg/m2,Oral semaglutide 50 mg group,treatment,535,0,0.0,33.7,6.2,33·7 (6·2)
NCT04707469,Waist circumference,"Waist circumference, cm",,continuous,cm,Oral semaglutide 14 mg group,treatment,536,0,0.0,112.0,14.0,112 (14)
NCT04707469,Waist circumference,"Waist circumference, cm",,continuous,cm,Oral semaglutide 25 mg group,treatment,535,0,0.0,113.0,14.0,113 (14)
NCT04707469,Waist circumference,"Waist circumference, cm",,continuous,cm,Oral semaglutide 50 mg group,treatment,535,0,0.0,112.0,15.0,112 (15)
NCT04707469,Systolic blood pressure,"Systolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 14 mg group,treatment,536,0,0.0,132.0,14.0,132 (14)
NCT04707469,Systolic blood pressure,"Systolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 25 mg group,treatment,535,0,0.0,133.0,14.0,133 (14)
NCT04707469,Systolic blood pressure,"Systolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 50 mg group,treatment,535,0,0.0,132.0,14.0,132 (14)
NCT04707469,Diastolic blood pressure,"Diastolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 14 mg group,treatment,536,0,0.0,81.0,9.0,81 (9)
NCT04707469,Diastolic blood pressure,"Diastolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 25 mg group,treatment,535,0,0.0,80.0,9.0,80 (9)
NCT04707469,Diastolic blood pressure,"Diastolic blood pressure, mm Hg",,continuous,mm Hg,Oral semaglutide 50 mg group,treatment,535,0,0.0,80.0,8.0,80 (8)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 14 mg group,treatment,536,514,96.0,0.0,0.0,514 (96%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 25 mg group,treatment,535,503,94.0,0.0,0.0,503 (94%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 50 mg group,treatment,535,507,95.0,0.0,0.0,507 (95%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 14 mg group,treatment,536,291,54.0,0.0,0.0,291 (54%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 25 mg group,treatment,535,287,54.0,0.0,0.0,287 (54%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 50 mg group,treatment,535,287,54.0,0.0,0.0,287 (54%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 14 mg group,treatment,536,163,30.0,0.0,0.0,163 (30%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 25 mg group,treatment,535,162,30.0,0.0,0.0,162 (30%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 50 mg group,treatment,535,159,30.0,0.0,0.0,159 (30%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 14 mg group,treatment,536,134,25.0,0.0,0.0,134 (25%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 25 mg group,treatment,535,136,25.0,0.0,0.0,136 (25%)
NCT04707469,Concomitant glucose-lowering medication,"Concomitant glucose-lowering medication, n",Concomitant glucose-lowering medication,categorical,,Oral semaglutide 50 mg group,treatment,535,133,25.0,0.0,0.0,133 (25%)
Exenatide (Exendin-4)_7,Sex - Male,Sex - N (%) Male:,Sex,categorical,%,Placebo,control,113,67,59.3,0.0,0.0,67 (59.3)
Exenatide (Exendin-4)_7,Sex - Female,Sex - N (%) Female:,Sex,categorical,%,Placebo,control,113,46,40.7,0.0,0.0,46 (40.7)
Exenatide (Exendin-4)_7,Race - Caucasian,Race - N (%) Caucasian,Race,categorical,%,Placebo,control,113,82,72.6,0.0,0.0,82 (72.6)
Exenatide (Exendin-4)_7,Race - Black,Race - N (%) Black,Race,categorical,%,Placebo,control,113,15,13.3,0.0,0.0,15 (13.3)
Exenatide (Exendin-4)_7,Race - Hispanic,Race - N (%) Hispanic,Race,categorical,%,Placebo,control,113,12,10.6,0.0,0.0,12 (10.6)
Exenatide (Exendin-4)_7,Race - Other,Race - N (%) Other,Race,categorical,%,Placebo,control,113,4,3.5,0.0,0.0,4 (3.5)
Exenatide (Exendin-4)_7,Age,Age (y):,,continuous,years,Placebo,control,113,0,0.0,54.0,9.0,54±9
Exenatide (Exendin-4)_7,Weight,Weight (kg):,,continuous,kg,Placebo,control,113,0,0.0,100.0,19.0,100±19
Exenatide (Exendin-4)_7,Body-Mass Index,Body-Mass Index (kg/m²):,,continuous,kg/m²,Placebo,control,113,0,0.0,34.0,6.0,34±6
Exenatide (Exendin-4)_7,Baseline A1C,Baseline A1C (%):,,continuous,%,Placebo,control,113,0,0.0,8.2,1.0,8.2±1.0
Exenatide (Exendin-4)_7,Fasting Plasma Glucose,Fasting Plasma Glucose (mg/dL):,,continuous,mg/dL,Placebo,control,113,0,0.0,170.0,40.0,170±40
Exenatide (Exendin-4)_7,Fasting Plasma Insulin,Fasting Plasma Insulin (pmol/L):,,continuous,pmol/L,Placebo,control,113,0,0.0,135.0,131.0,135±131
Exenatide (Exendin-4)_7,Fasting Plasma Proinsulin,Fasting Plasma Proinsulin (pmol/L):,,continuous,pmol/L,Placebo,control,113,0,0.0,58.0,48.0,58±48
Exenatide (Exendin-4)_7,Duration of Diabetes,Duration of Diabetes (y):,,continuous,years,Placebo,control,113,0,0.0,6.6,6.1,6.6±6.1
NCT04944992,Sex: Male,Male,Sex,categorical,,Efinopegdutide,treatment,72,39,54.2,0.0,0.0,39 (54.2)
NCT04944992,Sex: Female,Female,Sex,categorical,,Efinopegdutide,treatment,72,33,45.8,0.0,0.0,33 (45.8)
NCT04944992,Age,"Age, years",,continuous,years,Efinopegdutide,treatment,72,0,0.0,48.1,11.0,48.1 [11.0]
NCT00688701,Mean age,Mean age (years 6 SD),Demographics and baseline characteristics,continuous,years,Placebo combined,control,122,0,0.0,54.1,11.0,54.1 6 11.0
NCT00688701,Mean age,Mean age (years 6 SD),Demographics and baseline characteristics,continuous,years,Lixisenatide 2-Step,treatment,120,0,0.0,53.3,9.7,53.3 6 9.7
NCT00688701,Mean age,Mean age (years 6 SD),Demographics and baseline characteristics,continuous,years,Lixisenatide 1-Step,treatment,119,0,0.0,53.8,10.9,53.8 6 10.9
NCT00688701,Male,"Male, n (%)",Demographics and baseline characteristics,categorical,%,Placebo combined,control,122,60,49.2,0.0,0.0,60 (49.2)
NCT00688701,Male,"Male, n (%)",Demographics and baseline characteristics,categorical,%,Lixisenatide 2-Step,treatment,120,63,52.5,0.0,0.0,63 (52.5)
NCT00688701,Male,"Male, n (%)",Demographics and baseline characteristics,categorical,%,Lixisenatide 1-Step,treatment,119,63,52.9,0.0,0.0,63 (52.9)
NCT00688701,Race,Caucasian,"Race, n (%)",categorical,%,Placebo combined,control,122,90,73.8,0.0,0.0,90 (73.8)
NCT00688701,Race,Caucasian,"Race, n (%)",categorical,%,Lixisenatide 2-Step,treatment,120,88,73.3,0.0,0.0,88 (73.3)
NCT00688701,Race,Caucasian,"Race, n (%)",categorical,%,Lixisenatide 1-Step,treatment,119,85,71.4,0.0,0.0,85 (71.4)
NCT00688701,Race,Asian,"Race, n (%)",categorical,%,Placebo combined,control,122,24,19.7,0.0,0.0,24 (19.7)
NCT00688701,Race,Asian,"Race, n (%)",categorical,%,Lixisenatide 2-Step,treatment,120,27,22.5,0.0,0.0,27 (22.5)
NCT00688701,Race,Asian,"Race, n (%)",categorical,%,Lixisenatide 1-Step,treatment,119,29,24.4,0.0,0.0,29 (24.4)
NCT00688701,Race,Black,"Race, n (%)",categorical,%,Placebo combined,control,122,3,2.5,0.0,0.0,3 (2.5)
NCT00688701,Race,Black,"Race, n (%)",categorical,%,Lixisenatide 2-Step,treatment,120,0,0.0,0.0,0.0,0
NCT00688701,Race,Black,"Race, n (%)",categorical,%,Lixisenatide 1-Step,treatment,119,3,2.5,0.0,0.0,3 (2.5)
NCT00688701,Race,Other,"Race, n (%)",categorical,%,Placebo combined,control,122,5,4.1,0.0,0.0,5 (4.1)
NCT00688701,Race,Other,"Race, n (%)",categorical,%,Lixisenatide 2-Step,treatment,120,5,4.2,0.0,0.0,5 (4.2)
NCT00688701,Race,Other,"Race, n (%)",categorical,%,Lixisenatide 1-Step,treatment,119,2,1.7,0.0,0.0,2 (1.7)
NCT00688701,Median duration of diabetes,"Median duration of diabetes since diagnosis, years (range)",Demographics and baseline characteristics,continuous,years,Placebo combined,control,122,0,0.0,0.0,0.0,1.4 (0.2212.5)
NCT00688701,Median duration of diabetes,"Median duration of diabetes since diagnosis, years (range)",Demographics and baseline characteristics,continuous,years,Lixisenatide 2-Step,treatment,120,0,0.0,0.0,0.0,1.4 (0.2221.5)
NCT00688701,Median duration of diabetes,"Median duration of diabetes since diagnosis, years (range)",Demographics and baseline characteristics,continuous,years,Lixisenatide 1-Step,treatment,119,0,0.0,0.0,0.0,1.1 (0.2223.9)
NCT00688701,Mean HbA1c,"Mean HbA1c, % 6 SD (NGSP)",Demographics and baseline characteristics,continuous,%,Placebo combined,control,122,0,0.0,8.07,0.9,8.07 6 0.9
NCT00688701,Mean HbA1c,"Mean HbA1c, % 6 SD (NGSP)",Demographics and baseline characteristics,continuous,%,Lixisenatide 2-Step,treatment,120,0,0.0,7.98,0.9,7.98 6 0.9
NCT00688701,Mean HbA1c,"Mean HbA1c, % 6 SD (NGSP)",Demographics and baseline characteristics,continuous,%,Lixisenatide 1-Step,treatment,119,0,0.0,8.07,0.9,8.07 6 0.9
NCT00688701,Mean FPG,Mean FPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Placebo combined,control,122,0,0.0,8.9,2.2,8.9 6 2.2
NCT00688701,Mean FPG,Mean FPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 2-Step,treatment,120,0,0.0,9.2,2.0,9.2 6 2.0
NCT00688701,Mean FPG,Mean FPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 1-Step,treatment,119,0,0.0,9.0,2.0,9.0 6 2.0
NCT00688701,Mean 2-h PPG,Mean 2-h PPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Placebo combined,control,122,0,0.0,14.3,4.8,14.3 6 4.8
NCT00688701,Mean 2-h PPG,Mean 2-h PPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 2-Step,treatment,120,0,0.0,14.8,3.9,14.8 6 3.9
NCT00688701,Mean 2-h PPG,Mean 2-h PPG (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 1-Step,treatment,119,0,0.0,14.6,3.4,14.6 6 3.4
NCT00688701,Glucose excursion,Glucose excursion (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Placebo combined,control,122,0,0.0,4.8,3.7,4.8 6 3.7
NCT00688701,Glucose excursion,Glucose excursion (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 2-Step,treatment,120,0,0.0,5.7,3.1,5.7 6 3.1
NCT00688701,Glucose excursion,Glucose excursion (mmol/L 6 SD),Demographics and baseline characteristics,continuous,mmol/L,Lixisenatide 1-Step,treatment,119,0,0.0,5.3,3.0,5.3 6 3.0
NCT00688701,Mean weight,Mean weight (kg 6 SD),Demographics and baseline characteristics,continuous,kg,Placebo combined,control,122,0,0.0,86.1,22.0,86.1 6 22
NCT00688701,Mean weight,Mean weight (kg 6 SD),Demographics and baseline characteristics,continuous,kg,Lixisenatide 2-Step,treatment,120,0,0.0,89.0,22.0,89.0 6 22
NCT00688701,Mean weight,Mean weight (kg 6 SD),Demographics and baseline characteristics,continuous,kg,Lixisenatide 1-Step,treatment,119,0,0.0,86.5,21.0,86.5 6 21
NCT00688701,Mean BMI,Mean BMI (kg/m2 6 SD),Demographics and baseline characteristics,continuous,kg/m2,Placebo combined,control,122,0,0.0,31.8,6.7,31.8 6 6.7
NCT00688701,Mean BMI,Mean BMI (kg/m2 6 SD),Demographics and baseline characteristics,continuous,kg/m2,Lixisenatide 2-Step,treatment,120,0,0.0,32.3,6.7,32.3 6 6.7
NCT00688701,Mean BMI,Mean BMI (kg/m2 6 SD),Demographics and baseline characteristics,continuous,kg/m2,Lixisenatide 1-Step,treatment,119,0,0.0,31.7,6.6,31.7 6 6.6
NCT00308139,Sex,Sex (%),Demographics,categorical,%,Exenatide QW,treatment,120,68,57.0,0.0,0.0,68 (57%)
NCT00308139,Sex,Sex (%),Demographics,categorical,%,Exenatide BID -> Exenatide QW,treatment,121,64,53.0,0.0,0.0,64 (53%)
NCT00308139,Age,Age (y),Demographics,continuous,years,Exenatide QW,treatment,120,0,0.0,56.0,9.0,56 (9)
NCT00308139,Age,Age (y),Demographics,continuous,years,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,55.0,10.0,55 (10)
NCT00308139,Weight,Weight (kg),Demographics,continuous,kg,Exenatide QW,treatment,120,0,0.0,103.0,19.0,103 (19)
NCT00308139,Weight,Weight (kg),Demographics,continuous,kg,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,102.0,20.0,102 (20)
NCT00308139,Body Mass Index,Body Mass Index (kg/m²),Demographics,continuous,kg/m²,Exenatide QW,treatment,120,0,0.0,35.0,5.0,35 (5)
NCT00308139,Body Mass Index,Body Mass Index (kg/m²),Demographics,continuous,kg/m²,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,35.0,5.0,35 (5)
NCT00308139,A1C,A1C (%),Demographics,continuous,%,Exenatide QW,treatment,120,0,0.0,8.3,1.0,8.3 (1.0)
NCT00308139,A1C,A1C (%),Demographics,continuous,%,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,8.2,0.9,8.2 (0.9)
NCT00308139,Fasting Plasma Glucose,Fasting Plasma Glucose (mg/dL),Demographics,continuous,mg/dL,Exenatide QW,treatment,120,0,0.0,172.0,45.0,172 (45)
NCT00308139,Fasting Plasma Glucose,Fasting Plasma Glucose (mg/dL),Demographics,continuous,mg/dL,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,166.0,41.0,166 (41)
NCT00308139,Duration of Diabetes,Duration of Diabetes (y),Demographics,continuous,years,Exenatide QW,treatment,120,0,0.0,7.0,6.0,7 (6)
NCT00308139,Duration of Diabetes,Duration of Diabetes (y),Demographics,continuous,years,Exenatide BID -> Exenatide QW,treatment,121,0,0.0,6.0,5.0,6(5)
NCT05669599,Age,Age-yr,,continuous,years,140 mg Every 4 Wk,treatment,77,0,0.0,45.6,12.2,45.6±12.2
NCT05669599,Age,Age-yr,,continuous,years,280 mg Every 4 Wk,treatment,77,0,0.0,49.4,12.6,49.4±12.6
NCT05669599,Age,Age-yr,,continuous,years,420 mg Every 4 Wk,treatment,79,0,0.0,49.1,13.0,49.1±13.0
NCT05669599,Age,Age-yr,,continuous,years,420 mg Every 8 Wk,treatment,51,0,0.0,47.6,11.0,47.6±11.0
NCT05669599,Age,Age-yr,,continuous,years,"420 mg Every 4 Wk, with 4-Wk DE",treatment,51,0,0.0,49.0,11.4,49.0±11.4
NCT05669599,Age,Age-yr,,continuous,years,"420 mg Every 4 Wk, with 12-Wk DE",treatment,52,0,0.0,48.2,12.5,48.2±12.5
NCT05669599,Age,Age-yr,,continuous,years,Placebo,control,78,0,0.0,47.0,12.9,47.0±12.9
NCT05669599,Age,Age-yr,,continuous,years,140 mg Every 4 Wk,treatment,31,0,0.0,54.9,12.8,54.9±12.8
NCT05669599,Age,Age-yr,,continuous,years,280 mg Every 4 Wk,treatment,32,0,0.0,56.8,11.7,56.8±11.7
NCT05669599,Age,Age-yr,,continuous,years,420 mg Every 4 Wk,treatment,32,0,0.0,55.3,10.3,55.3±10.3
NCT05669599,Age,Age-yr,,continuous,years,Placebo,control,32,0,0.0,53.5,10.2,53.5±10.2
NCT05669599,Female sex,Female sex no. (%),,categorical,,140 mg Every 4 Wk,treatment,77,48,62.0,0.0,0.0,48 (62)
NCT05669599,Female sex,Female sex no. (%),,categorical,,280 mg Every 4 Wk,treatment,77,48,62.0,0.0,0.0,48 (62)
NCT05669599,Female sex,Female sex no. (%),,categorical,,420 mg Every 4 Wk,treatment,79,50,63.0,0.0,0.0,50 (63)
NCT05669599,Female sex,Female sex no. (%),,categorical,,420 mg Every 8 Wk,treatment,51,33,65.0,0.0,0.0,33 (65)
NCT05669599,Female sex,Female sex no. (%),,categorical,,"420 mg Every 4 Wk, with 4-Wk DE",treatment,51,31,61.0,0.0,0.0,31 (61)
NCT05669599,Female sex,Female sex no. (%),,categorical,,"420 mg Every 4 Wk, with 12-Wk DE",treatment,52,33,64.0,0.0,0.0,33 (64)
NCT05669599,Female sex,Female sex no. (%),,categorical,,Placebo,control,78,49,63.0,0.0,0.0,49 (63)
NCT05669599,Female sex,Female sex no. (%),,categorical,,140 mg Every 4 Wk,treatment,31,13,42.0,0.0,0.0,13 (42)
NCT05669599,Female sex,Female sex no. (%),,categorical,,280 mg Every 4 Wk,treatment,32,14,44.0,0.0,0.0,14 (44)
NCT05669599,Female sex,Female sex no. (%),,categorical,,420 mg Every 4 Wk,treatment,32,13,41.0,0.0,0.0,13 (41)
NCT05669599,Female sex,Female sex no. (%),,categorical,,Placebo,control,32,13,41.0,0.0,0.0,13 (41)
NCT00381342,Age,"Age, y",,continuous,years,Exenatide 5 μg,treatment,77,0,0.0,54.0,10.0,54 (10)
NCT00381342,Age,"Age, y",,continuous,years,Exenatide 10 μg,treatment,78,0,0.0,55.0,10.0,55 (10)
NCT00381342,Age,"Age, y",,continuous,years,Placebo,control,77,0,0.0,53.0,9.0,53 (9)
NCT00381342,Sex,"Sex, %",,categorical,%,Exenatide 5 μg,treatment,77,40,52.0,0.0,0.0,52
NCT00381342,Sex,"Sex, %",,categorical,%,Exenatide 10 μg,treatment,78,48,62.0,0.0,0.0,62
NCT00381342,Sex,"Sex, %",,categorical,%,Placebo,control,77,42,55.0,0.0,0.0,55
NCT00381342,Race,"Race, %",,categorical,%,Exenatide 5 μg,treatment,77,50,65.0,0.0,0.0,65
NCT00381342,Race,"Race, %",,categorical,%,Exenatide 10 μg,treatment,78,56,72.0,0.0,0.0,72
NCT00381342,Race,"Race, %",,categorical,%,Placebo,control,77,51,66.0,0.0,0.0,66
NCT00381342,Duration of diabetes,"Duration of diabetes, y",,continuous,years,Exenatide 5 μg,treatment,77,0,0.0,2.0,3.0,2 (3)
NCT00381342,Duration of diabetes,"Duration of diabetes, y",,continuous,years,Exenatide 10 μg,treatment,78,0,0.0,2.0,3.0,2 (3)
NCT00381342,Duration of diabetes,"Duration of diabetes, y",,continuous,years,Placebo,control,77,0,0.0,1.0,2.0,1 (2)
NCT00381342,HbA1c,HbA1c %,,continuous,%,Exenatide 5 μg,treatment,77,0,0.0,7.9,1.0,7.9 (1.0)
NCT00381342,HbA1c,HbA1c %,,continuous,%,Exenatide 10 μg,treatment,78,0,0.0,7.8,1.0,7.8 (1.0)
NCT00381342,HbA1c,HbA1c %,,continuous,%,Placebo,control,77,0,0.0,7.8,0.9,7.8 (0.9)
NCT00381342,FSG,"FSG, mg/dL",,continuous,mg/dL,Exenatide 5 μg,treatment,77,0,0.0,166.0,49.0,166 (49)
NCT00381342,FSG,"FSG, mg/dL",,continuous,mg/dL,Exenatide 10 μg,treatment,78,0,0.0,154.0,40.0,154 (40)
NCT00381342,FSG,"FSG, mg/dL",,continuous,mg/dL,Placebo,control,77,0,0.0,160.0,46.0,160 (46)
NCT00381342,Weight,"Weight, kg",,continuous,kg,Exenatide 5 μg,treatment,77,0,0.0,85.0,15.0,85 (15)
NCT00381342,Weight,"Weight, kg",,continuous,kg,Exenatide 10 μg,treatment,78,0,0.0,86.0,16.0,86 (16)
NCT00381342,Weight,"Weight, kg",,continuous,kg,Placebo,control,77,0,0.0,86.0,16.0,86 (16)
NCT00381342,BMI,"BMI, kg/m²",,continuous,kg/m²,Exenatide 5 μg,treatment,77,0,0.0,32.0,5.0,32 (5)
NCT00381342,BMI,"BMI, kg/m²",,continuous,kg/m²,Exenatide 10 μg,treatment,78,0,0.0,31.0,5.0,31 (5)
NCT00381342,BMI,"BMI, kg/m²",,continuous,kg/m²,Placebo,control,77,0,0.0,32.0,5.0,32 (5)
NCT00381342,SBP,"SBP, mm Hg",,continuous,mm Hg,Exenatide 5 μg,treatment,77,0,0.0,129.0,11.0,129 (11)
NCT00381342,SBP,"SBP, mm Hg",,continuous,mm Hg,Exenatide 10 μg,treatment,78,0,0.0,130.0,12.0,130 (12)
NCT00381342,SBP,"SBP, mm Hg",,continuous,mm Hg,Placebo,control,77,0,0.0,129.0,12.0,129 (12)
NCT00381342,DBP,"DBP, mm Hg",,continuous,mm Hg,Exenatide 5 μg,treatment,77,0,0.0,78.0,8.0,78 (8)
NCT00381342,DBP,"DBP, mm Hg",,continuous,mm Hg,Exenatide 10 μg,treatment,78,0,0.0,79.0,8.0,79 (8)
NCT00381342,DBP,"DBP, mm Hg",,continuous,mm Hg,Placebo,control,77,0,0.0,78.0,7.0,78 (7)
NCT02465515,Age,"Age, years",,continuous,years,Albiglutide,treatment,4731,0,0.0,64.1,8.7,64·1 (8·7)
NCT02465515,Age,"Age, years",,continuous,years,Placebo,control,4732,0,0.0,64.2,8.7,64·2 (8·7)
NCT02465515,Sex,Female,Sex,categorical,,Albiglutide,treatment,4731,1427,30.0,0.0,0.0,1427 (30%)
NCT02465515,Sex,Female,Sex,categorical,,Placebo,control,4732,1467,31.0,0.0,0.0,1467 (31%)
NCT02465515,Sex,Male,Sex,categorical,,Albiglutide,treatment,4731,3304,70.0,0.0,0.0,3304 (70%)
NCT02465515,Sex,Male,Sex,categorical,,Placebo,control,4732,3265,69.0,0.0,0.0,3265 (69%)
NCT02465515,Race or ethnicity,Non-Hispanic white,Race or ethnicity,categorical,,Albiglutide,treatment,4731,3295,70.0,0.0,0.0,3295 (70%)
NCT02465515,Race or ethnicity,Non-Hispanic white,Race or ethnicity,categorical,,Placebo,control,4732,3288,69.0,0.0,0.0,3288 (69%)
NCT02465515,Race or ethnicity,Asian,Race or ethnicity,categorical,,Albiglutide,treatment,4731,228,5.0,0.0,0.0,228 (5%)
NCT02465515,Race or ethnicity,Asian,Race or ethnicity,categorical,,Placebo,control,4732,242,5.0,0.0,0.0,242 (5%)
NCT02465515,Race or ethnicity,Non-Hispanic black or African-American,Race or ethnicity,categorical,,Albiglutide,treatment,4731,111,2.0,0.0,0.0,111 (2%)
NCT02465515,Race or ethnicity,Non-Hispanic black or African-American,Race or ethnicity,categorical,,Placebo,control,4732,114,2.0,0.0,0.0,114 (2%)
NCT02465515,Race or ethnicity,Hispanic,Race or ethnicity,categorical,,Albiglutide,treatment,4731,1005,21.0,0.0,0.0,1005 (21%)
NCT02465515,Race or ethnicity,Hispanic,Race or ethnicity,categorical,,Placebo,control,4732,988,21.0,0.0,0.0,988 (21%)
NCT02465515,Race or ethnicity,Other,Race or ethnicity,categorical,,Albiglutide,treatment,4731,92,2.0,0.0,0.0,92 (2%)
NCT02465515,Race or ethnicity,Other,Race or ethnicity,categorical,,Placebo,control,4732,100,2.0,0.0,0.0,100 (2%)
NCT02465515,Geographic region,Western Europe,Geographic region,categorical,,Albiglutide,treatment,4731,1684,36.0,0.0,0.0,1684 (36%)
NCT02465515,Geographic region,Western Europe,Geographic region,categorical,,Placebo,control,4732,1708,36.0,0.0,0.0,1708 (36%)
NCT02465515,Geographic region,Eastern and central Europe,Geographic region,categorical,,Albiglutide,treatment,4731,1037,22.0,0.0,0.0,1037 (22%)
NCT02465515,Geographic region,Eastern and central Europe,Geographic region,categorical,,Placebo,control,4732,1010,21.0,0.0,0.0,1010 (21%)
NCT02465515,Geographic region,North America,Geographic region,categorical,,Albiglutide,treatment,4731,967,20.0,0.0,0.0,967 (20%)
NCT02465515,Geographic region,North America,Geographic region,categorical,,Placebo,control,4732,978,21.0,0.0,0.0,978 (21%)
NCT02465515,Geographic region,Latin America,Geographic region,categorical,,Albiglutide,treatment,4731,858,18.0,0.0,0.0,858 (18%)
NCT02465515,Geographic region,Latin America,Geographic region,categorical,,Placebo,control,4732,845,18.0,0.0,0.0,845 (18%)
NCT02465515,Geographic region,Asia Pacific,Geographic region,categorical,,Albiglutide,treatment,4731,185,4.0,0.0,0.0,185 (4%)
NCT02465515,Geographic region,Asia Pacific,Geographic region,categorical,,Placebo,control,4732,191,4.0,0.0,0.0,191 (4%)
NCT02465515,Current smokers,Current smokers,,categorical,,Albiglutide,treatment,4731,737,16.0,0.0,0.0,737 (16%)
NCT02465515,Current smokers,Current smokers,,categorical,,Placebo,control,4732,751,16.0,0.0,0.0,751 (16%)
NCT02465515,Medical history,Coronary artery disease*,Medical history,categorical,,Albiglutide,treatment,4731,3333,70.0,0.0,0.0,3333 (70%)
NCT02465515,Medical history,Coronary artery disease*,Medical history,categorical,,Placebo,control,4732,3345,71.0,0.0,0.0,3345 (71%)
NCT02465515,Medical history,Hypertension,Medical history,categorical,,Albiglutide,treatment,4731,4089,86.0,0.0,0.0,4089 (86%)
NCT02465515,Medical history,Hypertension,Medical history,categorical,,Placebo,control,4732,4095,87.0,0.0,0.0,4095 (87%)
NCT02465515,Medical history,Myocardial infarction,Medical history,categorical,,Albiglutide,treatment,4731,2223,47.0,0.0,0.0,2223 (47%)
NCT02465515,Medical history,Myocardial infarction,Medical history,categorical,,Placebo,control,4732,2236,47.0,0.0,0.0,2236 (47%)
NCT02465515,Medical history,Coronary artery bypass surgery,Medical history,categorical,,Albiglutide,treatment,4731,890,19.0,0.0,0.0,890 (19%)
NCT02465515,Medical history,Coronary artery bypass surgery,Medical history,categorical,,Placebo,control,4732,842,18.0,0.0,0.0,842 (18%)
NCT02465515,Medical history,Percutaneous coronary intervention,Medical history,categorical,,Albiglutide,treatment,4731,2050,43.0,0.0,0.0,2050 (43%)
NCT02465515,Medical history,Percutaneous coronary intervention,Medical history,categorical,,Placebo,control,4732,2113,45.0,0.0,0.0,2113 (45%)
NCT02465515,Medical history,Stroke,Medical history,categorical,,Albiglutide,treatment,4731,827,17.0,0.0,0.0,827 (17%)
NCT02465515,Medical history,Stroke,Medical history,categorical,,Placebo,control,4732,854,18.0,0.0,0.0,854 (18%)
NCT02465515,Medical history,Peripheral artery disease,Medical history,categorical,,Albiglutide,treatment,4731,1195,25.0,0.0,0.0,1195 (25%)
NCT02465515,Medical history,Peripheral artery disease,Medical history,categorical,,Placebo,control,4732,1159,24.0,0.0,0.0,1159 (24%)
NCT02465515,Medical history,Heart failure,Medical history,categorical,,Albiglutide,treatment,4731,954,20.0,0.0,0.0,954 (20%)
NCT02465515,Medical history,Heart failure,Medical history,categorical,,Placebo,control,4732,968,20.0,0.0,0.0,968 (20%)
NCT02465515,Medical history,Atrial fibrillation,Medical history,categorical,,Albiglutide,treatment,4731,394,8.0,0.0,0.0,394 (8%)
NCT02465515,Medical history,Atrial fibrillation,Medical history,categorical,,Placebo,control,4732,392,8.0,0.0,0.0,392 (8%)
NCT02465515,Body-mass index,"Body-mass index, kg/m²",,continuous,kg/m²,Albiglutide,treatment,4731,0,0.0,32.3,5.9,32·3 (5·9)
NCT02465515,Body-mass index,"Body-mass index, kg/m²",,continuous,kg/m²,Placebo,control,4732,0,0.0,32.3,5.9,32·3 (5·9)
NCT02465515,Blood pressure,Systolic,Blood pressure,continuous,mm Hg,Albiglutide,treatment,4731,0,0.0,134.8,16.6,134·8 (16·6)
NCT02465515,Blood pressure,Systolic,Blood pressure,continuous,mm Hg,Placebo,control,4732,0,0.0,134.7,16.5,134·7 (16·5)
NCT02465515,Blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Albiglutide,treatment,4731,0,0.0,76.8,10.1,76·8 (10·1)
NCT02465515,Blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Placebo,control,4732,0,0.0,76.8,10.1,76·8 (10·1)
NCT02465515,Glycated haemoglobin,"Glycated haemoglobin, %",,continuous,%,Albiglutide,treatment,4731,0,0.0,8.76,1.5,8·76 (1·5)
NCT02465515,Glycated haemoglobin,"Glycated haemoglobin, %",,continuous,%,Placebo,control,4732,0,0.0,8.72,1.5,8·72 (1·5)
NCT02465515,eGFR,"eGFR, mL/min per 1·73 m²",,continuous,mL/min per 1·73 m²,Albiglutide,treatment,4731,0,0.0,79.1,25.6,79·1 (25·6)
NCT02465515,eGFR,"eGFR, mL/min per 1·73 m²",,continuous,mL/min per 1·73 m²,Placebo,control,4732,0,0.0,78.9,25.4,78·9 (25·4)
NCT02465515,Duration of diabetes,"Duration of diabetes, years",,continuous,years,Albiglutide,treatment,4731,0,0.0,14.1,8.6,14·1 (8·6)
NCT02465515,Duration of diabetes,"Duration of diabetes, years",,continuous,years,Placebo,control,4732,0,0.0,14.2,8.9,14·2 (8·9)
NCT02465515,History of microvascular disease,Diabetic eye disease,History of microvascular disease,categorical,,Albiglutide,treatment,4731,982,21.0,0.0,0.0,982 (21%)
NCT02465515,History of microvascular disease,Diabetic eye disease,History of microvascular disease,categorical,,Placebo,control,4732,955,20.0,0.0,0.0,955 (20%)
NCT02465515,History of microvascular disease,Nephropathy,History of microvascular disease,categorical,,Albiglutide,treatment,4731,898,19.0,0.0,0.0,898 (19%)
NCT02465515,History of microvascular disease,Nephropathy,History of microvascular disease,categorical,,Placebo,control,4732,840,18.0,0.0,0.0,840 (18%)
NCT02465515,History of microvascular disease,Peripheral sensory neuropathy,History of microvascular disease,categorical,,Albiglutide,treatment,4731,1562,33.0,0.0,0.0,1562 (33%)
NCT02465515,History of microvascular disease,Peripheral sensory neuropathy,History of microvascular disease,categorical,,Placebo,control,4732,1533,32.0,0.0,0.0,1533 (32%)
NCT02465515,History of microvascular disease,Autonomic neuropathy,History of microvascular disease,categorical,,Albiglutide,treatment,4731,143,3.0,0.0,0.0,143 (3%)
NCT02465515,History of microvascular disease,Autonomic neuropathy,History of microvascular disease,categorical,,Placebo,control,4732,107,2.0,0.0,0.0,107 (2%)
NCT02465515,Cardiovascular medications,Beta-blocker,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,3128,66.0,0.0,0.0,3128 (66%)
NCT02465515,Cardiovascular medications,Beta-blocker,Cardiovascular medications,categorical,,Placebo,control,4732,3182,67.0,0.0,0.0,3182 (67%)
NCT02465515,Cardiovascular medications,Calcium channel blocker,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,1428,30.0,0.0,0.0,1428 (30%)
NCT02465515,Cardiovascular medications,Calcium channel blocker,Cardiovascular medications,categorical,,Placebo,control,4732,1431,30.0,0.0,0.0,1431 (30%)
NCT02465515,Cardiovascular medications,Angiotensin-converting-enzyme inhibitor,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,2263,48.0,0.0,0.0,2263 (48%)
NCT02465515,Cardiovascular medications,Angiotensin-converting-enzyme inhibitor,Cardiovascular medications,categorical,,Placebo,control,4732,2353,50.0,0.0,0.0,2353 (50%)
NCT02465515,Cardiovascular medications,Angiotensin receptor blocker,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,1599,34.0,0.0,0.0,1599 (34%)
NCT02465515,Cardiovascular medications,Angiotensin receptor blocker,Cardiovascular medications,categorical,,Placebo,control,4732,1511,32.0,0.0,0.0,1511 (32%)
NCT02465515,Cardiovascular medications,Thiazide diuretic,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,1089,23.0,0.0,0.0,1089 (23%)
NCT02465515,Cardiovascular medications,Thiazide diuretic,Cardiovascular medications,categorical,,Placebo,control,4732,1037,22.0,0.0,0.0,1037 (22%)
NCT02465515,Cardiovascular medications,Loop diuretic,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,895,19.0,0.0,0.0,895 (19%)
NCT02465515,Cardiovascular medications,Loop diuretic,Cardiovascular medications,categorical,,Placebo,control,4732,899,19.0,0.0,0.0,899 (19%)
NCT02465515,Cardiovascular medications,Statin,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,3967,84.0,0.0,0.0,3967 (84%)
NCT02465515,Cardiovascular medications,Statin,Cardiovascular medications,categorical,,Placebo,control,4732,3988,84.0,0.0,0.0,3988 (84%)
NCT02465515,Cardiovascular medications,Aspirin,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,3652,77.0,0.0,0.0,3652 (77%)
NCT02465515,Cardiovascular medications,Aspirin,Cardiovascular medications,categorical,,Placebo,control,4732,3639,77.0,0.0,0.0,3639 (77%)
NCT02465515,Cardiovascular medications,P2Y12 inhibitor,Cardiovascular medications,categorical,,Albiglutide,treatment,4731,1224,26.0,0.0,0.0,1224 (26%)
NCT02465515,Cardiovascular medications,P2Y12 inhibitor,Cardiovascular medications,categorical,,Placebo,control,4732,1251,26.0,0.0,0.0,1251 (26%)
NCT02465515,Glucose-lowering medications,None or diet,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,42,1.0,0.0,0.0,42 (1%)
NCT02465515,Glucose-lowering medications,None or diet,Glucose-lowering medications,categorical,,Placebo,control,4732,35,1.0,0.0,0.0,35 (1%)
NCT02465515,Glucose-lowering medications,Biguanide,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,3463,73.0,0.0,0.0,3463 (73%)
NCT02465515,Glucose-lowering medications,Biguanide,Glucose-lowering medications,categorical,,Placebo,control,4732,3506,74.0,0.0,0.0,3506 (74%)
NCT02465515,Glucose-lowering medications,Sulfonylurea,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,1346,28.0,0.0,0.0,1346 (28%)
NCT02465515,Glucose-lowering medications,Sulfonylurea,Glucose-lowering medications,categorical,,Placebo,control,4732,1379,29.0,0.0,0.0,1379 (29%)
NCT02465515,Glucose-lowering medications,Insulin,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,2860,60.0,0.0,0.0,2860 (60%)
NCT02465515,Glucose-lowering medications,Insulin,Glucose-lowering medications,categorical,,Placebo,control,4732,2737,58.0,0.0,0.0,2737 (58%)
NCT02465515,Glucose-lowering medications,Dipeptidyl peptidase 4 inhibitor,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,698,15.0,0.0,0.0,698 (15%)
NCT02465515,Glucose-lowering medications,Dipeptidyl peptidase 4 inhibitor,Glucose-lowering medications,categorical,,Placebo,control,4732,739,16.0,0.0,0.0,739 (16%)
NCT02465515,Glucose-lowering medications,Sodium-glucose cotransporter,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,310,7.0,0.0,0.0,310 (7%)
NCT02465515,Glucose-lowering medications,Sodium-glucose cotransporter,Glucose-lowering medications,categorical,,Placebo,control,4732,265,6.0,0.0,0.0,265 (6%)
NCT02465515,Glucose-lowering medications,2 inhibitor,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,0,0.0,0.0,0.0,
NCT02465515,Glucose-lowering medications,2 inhibitor,Glucose-lowering medications,categorical,,Placebo,control,4732,0,0.0,0.0,0.0,
NCT02465515,Glucose-lowering medications,Thiazolidinedione,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,92,2.0,0.0,0.0,92 (2%)
NCT02465515,Glucose-lowering medications,Thiazolidinedione,Glucose-lowering medications,categorical,,Placebo,control,4732,102,2.0,0.0,0.0,102 (2%)
NCT02465515,Glucose-lowering medications,Glinide,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,66,1.0,0.0,0.0,66 (1%)
NCT02465515,Glucose-lowering medications,Glinide,Glucose-lowering medications,categorical,,Placebo,control,4732,96,2.0,0.0,0.0,96 (2%)
NCT02465515,Glucose-lowering medications,α-glucosidase inhibitor,Glucose-lowering medications,categorical,,Albiglutide,treatment,4731,34,1.0,0.0,0.0,34 (1%)
NCT02465515,Glucose-lowering medications,α-glucosidase inhibitor,Glucose-lowering medications,categorical,,Placebo,control,4732,37,1.0,0.0,0.0,37 (1%)
NCT04184622,Age,Age — yr,,continuous,years,"Tirzepatide, 5 mg",treatment,630,0,0.0,45.6,12.7,45.6±12.7
NCT04184622,Age,Age — yr,,continuous,years,"Tirzepatide, 10 mg",treatment,636,0,0.0,44.7,12.4,44.7±12.4
NCT04184622,Age,Age — yr,,continuous,years,"Tirzepatide, 15 mg",treatment,630,0,0.0,44.9,12.3,44.9±12.3
NCT04184622,Age,Age — yr,,continuous,years,Placebo,control,643,0,0.0,44.4,12.5,44.4±12.5
NCT04184622,Female sex,Female sex — no. (%),,categorical,,"Tirzepatide, 5 mg",treatment,630,426,67.6,0.0,0.0,426 (67.6)
NCT04184622,Female sex,Female sex — no. (%),,categorical,,"Tirzepatide, 10 mg",treatment,636,427,67.1,0.0,0.0,427 (67.1)
NCT04184622,Female sex,Female sex — no. (%),,categorical,,"Tirzepatide, 15 mg",treatment,630,425,67.5,0.0,0.0,425 (67.5)
NCT04184622,Female sex,Female sex — no. (%),,categorical,,Placebo,control,643,436,67.8,0.0,0.0,436 (67.8)
NCT04184622,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,56,8.9,0.0,0.0,56 (8.9)
NCT04184622,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,58,9.1,0.0,0.0,58 (9.1)
NCT04184622,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,59,9.4,0.0,0.0,59 (9.4)
NCT04184622,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,Placebo,control,643,58,9.0,0.0,0.0,58 (9.0)
NCT04184622,Race or ethnic group,Asian,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,68,10.8,0.0,0.0,68 (10.8)
NCT04184622,Race or ethnic group,Asian,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,71,11.2,0.0,0.0,71 (11.2)
NCT04184622,Race or ethnic group,Asian,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,66,10.5,0.0,0.0,66 (10.5)
NCT04184622,Race or ethnic group,Asian,Race or ethnic group,categorical,,Placebo,control,643,71,11.0,0.0,0.0,71 (11.0)
NCT04184622,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,48,7.6,0.0,0.0,48 (7.6)
NCT04184622,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,47,7.4,0.0,0.0,47 (7.4)
NCT04184622,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,51,8.1,0.0,0.0,51 (8.1)
NCT04184622,Race or ethnic group,Black or African American,Race or ethnic group,categorical,,Placebo,control,643,55,8.6,0.0,0.0,55 (8.6)
NCT04184622,Race or ethnic group,White,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,447,71.0,0.0,0.0,447 (71.0)
NCT04184622,Race or ethnic group,White,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,452,71.1,0.0,0.0,452 (71.1)
NCT04184622,Race or ethnic group,White,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,443,70.3,0.0,0.0,443 (70.3)
NCT04184622,Race or ethnic group,White,Race or ethnic group,categorical,,Placebo,control,643,450,70.0,0.0,0.0,450 (70.0)
NCT04184622,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,2,0.3,0.0,0.0,2 (0.3)
NCT04184622,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,2,0.3,0.0,0.0,2 (0.3)
NCT04184622,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,3,0.5,0.0,0.0,3 (0.5)
NCT04184622,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,Placebo,control,643,2,0.3,0.0,0.0,2 (0.3)
NCT04184622,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"Tirzepatide, 5 mg",treatment,630,9,1.4,0.0,0.0,9 (1.4)
NCT04184622,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"Tirzepatide, 10 mg",treatment,636,6,0.9,0.0,0.0,6 (0.9)
NCT04184622,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"Tirzepatide, 15 mg",treatment,630,8,1.3,0.0,0.0,8 (1.3)
NCT04184622,Race or ethnic group,Multiple,Race or ethnic group,categorical,,Placebo,control,643,7,1.1,0.0,0.0,7 (1.1)
NCT04184622,Hispanic or Latino,Hispanic or Latino — no. (%),,categorical,,"Tirzepatide, 5 mg",treatment,630,308,48.9,0.0,0.0,308 (48.9)
NCT04184622,Hispanic or Latino,Hispanic or Latino — no. (%),,categorical,,"Tirzepatide, 10 mg",treatment,636,297,46.7,0.0,0.0,297 (46.7)
NCT04184622,Hispanic or Latino,Hispanic or Latino — no. (%),,categorical,,"Tirzepatide, 15 mg",treatment,630,299,47.5,0.0,0.0,299 (47.5)
NCT04184622,Hispanic or Latino,Hispanic or Latino — no. (%),,categorical,,Placebo,control,643,310,48.2,0.0,0.0,310 (48.2)
NCT04184622,Duration of obesity,Duration of obesity — yr,,continuous,years,"Tirzepatide, 5 mg",treatment,630,0,0.0,14.0,10.81,14.0±10.81
NCT04184622,Duration of obesity,Duration of obesity — yr,,continuous,years,"Tirzepatide, 10 mg",treatment,636,0,0.0,14.7,11.05,14.7±11.05
NCT04184622,Duration of obesity,Duration of obesity — yr,,continuous,years,"Tirzepatide, 15 mg",treatment,630,0,0.0,14.8,10.75,14.8±10.75
NCT04184622,Duration of obesity,Duration of obesity — yr,,continuous,years,Placebo,control,643,0,0.0,14.0,10.71,14.0±10.71
NCT04184622,Body weight,Body weight — kg,,continuous,kg,"Tirzepatide, 5 mg",treatment,630,0,0.0,102.9,20.71,102.9±20.71
NCT04184622,Body weight,Body weight — kg,,continuous,kg,"Tirzepatide, 10 mg",treatment,636,0,0.0,105.8,23.32,105.8±23.32
NCT04184622,Body weight,Body weight — kg,,continuous,kg,"Tirzepatide, 15 mg",treatment,630,0,0.0,105.6,22.92,105.6±22.92
NCT04184622,Body weight,Body weight — kg,,continuous,kg,Placebo,control,643,0,0.0,104.8,21.37,104.8±21.37
NCT04184622,Mean body-mass index,Mean body-mass index,,continuous,,"Tirzepatide, 5 mg",treatment,630,0,0.0,37.4,6.63,37.4±6.63
NCT04184622,Mean body-mass index,Mean body-mass index,,continuous,,"Tirzepatide, 10 mg",treatment,636,0,0.0,38.2,7.01,38.2±7.01
NCT04184622,Mean body-mass index,Mean body-mass index,,continuous,,"Tirzepatide, 15 mg",treatment,630,0,0.0,38.1,6.69,38.1±6.69
NCT04184622,Mean body-mass index,Mean body-mass index,,continuous,,Placebo,control,643,0,0.0,38.2,6.89,38.2±6.89
NCT04184622,Body-mass index category,<30,Body-mass index category,categorical,,"Tirzepatide, 5 mg",treatment,630,38,6.0,0.0,0.0,38 (6.0)
NCT04184622,Body-mass index category,<30,Body-mass index category,categorical,,"Tirzepatide, 10 mg",treatment,636,38,6.0,0.0,0.0,38 (6.0)
NCT04184622,Body-mass index category,<30,Body-mass index category,categorical,,"Tirzepatide, 15 mg",treatment,630,40,6.3,0.0,0.0,40 (6.3)
NCT04184622,Body-mass index category,<30,Body-mass index category,categorical,,Placebo,control,643,24,3.7,0.0,0.0,24 (3.7)
NCT04184622,Body-mass index category,≥30 to <35,Body-mass index category,categorical,,"Tirzepatide, 5 mg",treatment,630,241,38.3,0.0,0.0,241 (38.3)
NCT04184622,Body-mass index category,≥30 to <35,Body-mass index category,categorical,,"Tirzepatide, 10 mg",treatment,636,209,32.9,0.0,0.0,209 (32.9)
NCT04184622,Body-mass index category,≥30 to <35,Body-mass index category,categorical,,"Tirzepatide, 15 mg",treatment,630,199,31.6,0.0,0.0,199 (31.6)
NCT04184622,Body-mass index category,≥30 to <35,Body-mass index category,categorical,,Placebo,control,643,227,35.3,0.0,0.0,227 (35.3)
NCT04184622,Body-mass index category,≥35 to <40,Body-mass index category,categorical,,"Tirzepatide, 5 mg",treatment,630,174,27.6,0.0,0.0,174 (27.6)
NCT04184622,Body-mass index category,≥35 to <40,Body-mass index category,categorical,,"Tirzepatide, 10 mg",treatment,636,187,29.4,0.0,0.0,187 (29.4)
NCT04184622,Body-mass index category,≥35 to <40,Body-mass index category,categorical,,"Tirzepatide, 15 mg",treatment,630,179,28.4,0.0,0.0,179 (28.4)
NCT04184622,Body-mass index category,≥35 to <40,Body-mass index category,categorical,,Placebo,control,643,180,28.0,0.0,0.0,180 (28.0)
NCT04184622,Body-mass index category,≥40,Body-mass index category,categorical,,"Tirzepatide, 5 mg",treatment,630,177,28.1,0.0,0.0,177 (28.1)
NCT04184622,Body-mass index category,≥40,Body-mass index category,categorical,,"Tirzepatide, 10 mg",treatment,636,202,31.8,0.0,0.0,202 (31.8)
NCT04184622,Body-mass index category,≥40,Body-mass index category,categorical,,"Tirzepatide, 15 mg",treatment,630,212,33.7,0.0,0.0,212 (33.7)
NCT04184622,Body-mass index category,≥40,Body-mass index category,categorical,,Placebo,control,643,212,33.0,0.0,0.0,212 (33.0)
NCT04184622,Waist circumference,Waist circumference — cm,,continuous,cm,"Tirzepatide, 5 mg",treatment,630,0,0.0,113.2,14.25,113.2±14.25
NCT04184622,Waist circumference,Waist circumference — cm,,continuous,cm,"Tirzepatide, 10 mg",treatment,636,0,0.0,114.8,15.8,114.8±15.80
NCT04184622,Waist circumference,Waist circumference — cm,,continuous,cm,"Tirzepatide, 15 mg",treatment,630,0,0.0,114.4,15.59,114.4±15.59
NCT04184622,Waist circumference,Waist circumference — cm,,continuous,cm,Placebo,control,643,0,0.0,114.0,14.92,114.0±14.92
NCT04184622,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 5 mg",treatment,630,0,0.0,123.6,12.45,123.6±12.45
NCT04184622,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 10 mg",treatment,636,0,0.0,123.8,12.77,123.8±12.77
NCT04184622,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 15 mg",treatment,630,0,0.0,123.0,12.94,123.0±12.94
NCT04184622,Systolic blood pressure,Systolic,Blood pressure,continuous,mm Hg,Placebo,control,643,0,0.0,122.9,12.77,122.9±12.77
NCT04184622,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 5 mg",treatment,630,0,0.0,79.3,8.14,79.3±8.14
NCT04184622,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 10 mg",treatment,636,0,0.0,79.9,8.32,79.9±8.32
NCT04184622,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,"Tirzepatide, 15 mg",treatment,630,0,0.0,79.3,8.23,79.3±8.23
NCT04184622,Diastolic blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Placebo,control,643,0,0.0,79.6,7.95,79.6±7.95
NCT04184622,Pulse,Pulse — beats per min,,continuous,beats per min,"Tirzepatide, 5 mg",treatment,630,0,0.0,72.3,9.6,72.3±9.60
NCT04184622,Pulse,Pulse — beats per min,,continuous,beats per min,"Tirzepatide, 10 mg",treatment,636,0,0.0,71.8,9.57,71.8±9.57
NCT04184622,Pulse,Pulse — beats per min,,continuous,beats per min,"Tirzepatide, 15 mg",treatment,630,0,0.0,72.5,9.95,72.5±9.95
NCT04184622,Pulse,Pulse — beats per min,,continuous,beats per min,Placebo,control,643,0,0.0,72.9,9.27,72.9±9.27
NCT04184622,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 5 mg",treatment,630,0,0.0,187.1,21.1,187.1 (21.1)
NCT04184622,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 10 mg",treatment,636,0,0.0,190.7,19.9,190.7 (19.9)
NCT04184622,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 15 mg",treatment,630,0,0.0,187.4,19.9,187.4 (19.9)
NCT04184622,Total cholesterol,Total cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,643,0,0.0,186.4,20.3,186.4 (20.3)
NCT04184622,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 5 mg",treatment,630,0,0.0,47.6,26.6,47.6 (26.6)
NCT04184622,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 10 mg",treatment,636,0,0.0,47.5,26.1,47.5 (26.1)
NCT04184622,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 15 mg",treatment,630,0,0.0,47.5,25.5,47.5 (25.5)
NCT04184622,HDL cholesterol,HDL cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,643,0,0.0,46.5,26.9,46.5 (26.9)
NCT04184622,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 5 mg",treatment,630,0,0.0,108.7,30.2,108.7 (30.2)
NCT04184622,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 10 mg",treatment,636,0,0.0,111.5,30.3,111.5 (30.3)
NCT04184622,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,"Tirzepatide, 15 mg",treatment,630,0,0.0,109.5,30.0,109.5 (30.0)
NCT04184622,LDL cholesterol,LDL cholesterol,Lipid levels,continuous,mg/dl,Placebo,control,643,0,0.0,108.4,30.5,108.4 (30.5)
NCT04184622,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,"Tirzepatide, 5 mg",treatment,630,0,0.0,128.9,51.7,128.9 (51.7)
NCT04184622,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,"Tirzepatide, 10 mg",treatment,636,0,0.0,126.5,51.5,126.5 (51.5)
NCT04184622,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,"Tirzepatide, 15 mg",treatment,630,0,0.0,127.9,47.5,127.9 (47.5)
NCT04184622,Triglycerides,Triglycerides,Lipid levels,continuous,mg/dl,Placebo,control,643,0,0.0,130.5,49.2,130.5 (49.2)
NCT04184622,Estimated GFR,Estimated GFR — ml/min/1.73 m2,,continuous,ml/min/1.73 m2,"Tirzepatide, 5 mg",treatment,630,0,0.0,97.6,17.87,97.6±17.87
NCT04184622,Estimated GFR,Estimated GFR — ml/min/1.73 m2,,continuous,ml/min/1.73 m2,"Tirzepatide, 10 mg",treatment,636,0,0.0,98.3,18.26,98.3±18.26
NCT04184622,Estimated GFR,Estimated GFR — ml/min/1.73 m2,,continuous,ml/min/1.73 m2,"Tirzepatide, 15 mg",treatment,630,0,0.0,98.2,17.67,98.2±17.67
NCT04184622,Estimated GFR,Estimated GFR — ml/min/1.73 m2,,continuous,ml/min/1.73 m2,Placebo,control,643,0,0.0,98.1,18.28,98.1±18.28
NCT04184622,Prediabetes,"Prediabetes, no. (%)",,categorical,,"Tirzepatide, 5 mg",treatment,630,247,39.2,0.0,0.0,247 (39.2)
NCT04184622,Prediabetes,"Prediabetes, no. (%)",,categorical,,"Tirzepatide, 10 mg",treatment,636,262,41.2,0.0,0.0,262 (41.2)
NCT04184622,Prediabetes,"Prediabetes, no. (%)",,categorical,,"Tirzepatide, 15 mg",treatment,630,253,40.2,0.0,0.0,253 (40.2)
NCT04184622,Prediabetes,"Prediabetes, no. (%)",,categorical,,Placebo,control,643,270,42.0,0.0,0.0,270 (42.0)
NCT04184622,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,"Tirzepatide, 5 mg",treatment,630,0,0.0,5.6,0.36,5.6±0.36
NCT04184622,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,"Tirzepatide, 10 mg",treatment,636,0,0.0,5.6,0.37,5.6±0.37
NCT04184622,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,"Tirzepatide, 15 mg",treatment,630,0,0.0,5.6,0.41,5.6±0.41
NCT04184622,Glycated hemoglobin,Glycated hemoglobin — %,,continuous,%,Placebo,control,643,0,0.0,5.6,0.38,5.6±0.38
NCT04184622,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,"Tirzepatide, 5 mg",treatment,630,0,0.0,95.4,9.7,95.4±9.7
NCT04184622,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,"Tirzepatide, 10 mg",treatment,636,0,0.0,95.5,10.7,95.5±10.7
NCT04184622,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,"Tirzepatide, 15 mg",treatment,630,0,0.0,95.3,10.3,95.3±10.3
NCT04184622,Fasting glucose,Fasting glucose — mg/dl,,continuous,mg/dl,Placebo,control,643,0,0.0,95.7,9.5,95.7±9.5
NCT04184622,Fasting insulin,Fasting insulin — mIU/liter,,continuous,mIU/liter,"Tirzepatide, 5 mg",treatment,630,0,0.0,13.6,10.0,13.6±10.0
NCT04184622,Fasting insulin,Fasting insulin — mIU/liter,,continuous,mIU/liter,"Tirzepatide, 10 mg",treatment,636,0,0.0,14.1,12.2,14.1±12.2
NCT04184622,Fasting insulin,Fasting insulin — mIU/liter,,continuous,mIU/liter,"Tirzepatide, 15 mg",treatment,630,0,0.0,14.4,9.3,14.4±9.3
NCT04184622,Fasting insulin,Fasting insulin — mIU/liter,,continuous,mIU/liter,Placebo,control,643,0,0.0,14.3,9.9,14.3±9.9
NCT04184622,SF-36 physical function score,SF-36 physical function score,,continuous,,"Tirzepatide, 5 mg",treatment,630,0,0.0,49.6,8.3,49.6±8.3
NCT04184622,SF-36 physical function score,SF-36 physical function score,,continuous,,"Tirzepatide, 10 mg",treatment,636,0,0.0,49.6,7.5,49.6±7.5
NCT04184622,SF-36 physical function score,SF-36 physical function score,,continuous,,"Tirzepatide, 15 mg",treatment,630,0,0.0,49.6,7.8,49.6±7.8
NCT04184622,SF-36 physical function score,SF-36 physical function score,,continuous,,Placebo,control,643,0,0.0,49.7,7.7,49.7±7.7
NCT00707031,Male,"Male/female, %",Gender,categorical,%,Lixisenatide 20 mg QD,treatment,318,151,47.5,0.0,0.0,47.5/52.5
NCT00707031,Female,"Male/female, %",Gender,categorical,%,Lixisenatide 20 mg QD,treatment,318,167,52.5,0.0,0.0,47.5/52.5
NCT00707031,Male,"Male/female, %",Gender,categorical,%,Exenatide 10 mg BID,control,316,187,59.2,0.0,0.0,59.2/40.8
NCT00707031,Female,"Male/female, %",Gender,categorical,%,Exenatide 10 mg BID,control,316,129,40.8,0.0,0.0,59.2/40.8
NCT00707031,Caucasian,"Caucasian/black/Asian/other race, %",Race,categorical,%,Lixisenatide 20 mg QD,treatment,318,296,93.1,0.0,0.0,93.1/2.5/0.9/3.5
NCT00707031,Black,"Caucasian/black/Asian/other race, %",Race,categorical,%,Lixisenatide 20 mg QD,treatment,318,8,2.5,0.0,0.0,93.1/2.5/0.9/3.5
NCT00707031,Asian,"Caucasian/black/Asian/other race, %",Race,categorical,%,Lixisenatide 20 mg QD,treatment,318,3,0.9,0.0,0.0,93.1/2.5/0.9/3.5
NCT00707031,Other,"Caucasian/black/Asian/other race, %",Race,categorical,%,Lixisenatide 20 mg QD,treatment,318,11,3.5,0.0,0.0,93.1/2.5/0.9/3.5
NCT00707031,Caucasian,"Caucasian/black/Asian/other race, %",Race,categorical,%,Exenatide 10 mg BID,control,316,292,92.4,0.0,0.0,92.4/3.2/1.3/3.2
NCT00707031,Black,"Caucasian/black/Asian/other race, %",Race,categorical,%,Exenatide 10 mg BID,control,316,10,3.2,0.0,0.0,92.4/3.2/1.3/3.2
NCT00707031,Asian,"Caucasian/black/Asian/other race, %",Race,categorical,%,Exenatide 10 mg BID,control,316,4,1.3,0.0,0.0,92.4/3.2/1.3/3.2
NCT00707031,Other,"Caucasian/black/Asian/other race, %",Race,categorical,%,Exenatide 10 mg BID,control,316,10,3.2,0.0,0.0,92.4/3.2/1.3/3.2
NCT00707031,Age,"Age (years), mean 6 SD",,continuous,years,Lixisenatide 20 mg QD,treatment,318,0,0.0,57.3,9.2,57.3 6 9.2
NCT00707031,Age,"Age (years), mean 6 SD",,continuous,years,Exenatide 10 mg BID,control,316,0,0.0,57.6,10.7,57.6 6 10.7
NCT00707031,Duration of diabetes,"Duration of diabetes (years), mean 6 SD",,continuous,years,Lixisenatide 20 mg QD,treatment,318,0,0.0,6.8,5.5,6.8 6 5.5
NCT00707031,Duration of diabetes,"Duration of diabetes (years), mean 6 SD",,continuous,years,Exenatide 10 mg BID,control,316,0,0.0,6.8,4.9,6.8 6 4.9
NCT00707031,Weight,"Weight (kg), mean 6 SD",,continuous,kg,Lixisenatide 20 mg QD,treatment,318,0,0.0,94.0,19.6,94.0 6 19.6
NCT00707031,Weight,"Weight (kg), mean 6 SD",,continuous,kg,Exenatide 10 mg BID,control,316,0,0.0,96.1,22.5,96.1 6 22.5
NCT00707031,BMI,"BMI (kg/m2), mean 6 SD",,continuous,kg/m2,Lixisenatide 20 mg QD,treatment,318,0,0.0,33.7,6.3,33.7 6 6.3
NCT00707031,BMI,"BMI (kg/m2), mean 6 SD",,continuous,kg/m2,Exenatide 10 mg BID,control,316,0,0.0,33.5,6.5,33.5 6 6.5
NCT00707031,HbA1c,"HbA1c (%), mean 6 SD",,continuous,%,Lixisenatide 20 mg QD,treatment,318,0,0.0,8.03,0.8,8.03 6 0.8
NCT00707031,HbA1c,"HbA1c (%), mean 6 SD",,continuous,%,Exenatide 10 mg BID,control,316,0,0.0,8.02,0.8,8.02 6 0.8
NCT00707031,FPG,"FPG (mmol/L [mg/dL]), mean 6 SD",,continuous,mmol/L,Lixisenatide 20 mg QD,treatment,318,0,0.0,9.7,2.0,9.7 6 2.0 (174.6 6 36.0)
NCT00707031,FPG,"FPG (mmol/L [mg/dL]), mean 6 SD",,continuous,mmol/L,Exenatide 10 mg BID,control,316,0,0.0,9.7,2.3,9.7 6 2.3 (174.6 6 41.4)
NCT00707031,PAGI-QOL total score,PAGI-QOL total score,,continuous,,Lixisenatide 20 mg QD,treatment,318,0,0.0,0.59,0.7,0.59 6 0.7
NCT00707031,PAGI-QOL total score,PAGI-QOL total score,,continuous,,Exenatide 10 mg BID,control,316,0,0.0,0.56,0.7,0.56 6 0.7
NCT00707031,Daily metformin dose,"Daily metformin dose (mg), mean 6 SD",,continuous,mg,Lixisenatide 20 mg QD,treatment,318,0,0.0,2020.0,459.0,"2,020 6 459"
NCT00707031,Daily metformin dose,"Daily metformin dose (mg), mean 6 SD",,continuous,mg,Exenatide 10 mg BID,control,316,0,0.0,2058.0,453.0,"2,058 6 453"
NCT05035095,Age,"Age, years",,continuous,years,Oral semaglutide 50 mg,treatment,334,0,0.0,49.0,13.0,49 (13)
NCT05035095,Age,"Age, years",,continuous,years,Placebo,control,333,0,0.0,50.0,12.0,50 (12)
NCT05035095,Sex,Female,Sex,categorical,,Oral semaglutide 50 mg,treatment,334,247,74.0,0.0,0.0,247/334 (74%)
NCT05035095,Sex,Female,Sex,categorical,,Placebo,control,333,238,71.0,0.0,0.0,238/333 (71%)
NCT05035095,Sex,Male,Sex,categorical,,Oral semaglutide 50 mg,treatment,334,87,26.0,0.0,0.0,87/334 (26%)
NCT05035095,Sex,Male,Sex,categorical,,Placebo,control,333,95,29.0,0.0,0.0,95/333 (29%)
NCT05035095,Race,Asian,Race,categorical,,Oral semaglutide 50 mg,treatment,334,36,11.0,0.0,0.0,36/334 (11%)
NCT05035095,Race,Asian,Race,categorical,,Placebo,control,333,36,11.0,0.0,0.0,36/333 (11%)
NCT05035095,Race,Black or African American,Race,categorical,,Oral semaglutide 50 mg,treatment,334,21,6.0,0.0,0.0,21/334 (6%)
NCT05035095,Race,Black or African American,Race,categorical,,Placebo,control,333,22,7.0,0.0,0.0,22/333 (7%)
NCT05035095,Race,White,Race,categorical,,Oral semaglutide 50 mg,treatment,334,246,74.0,0.0,0.0,246/334 (74%)
NCT05035095,Race,White,Race,categorical,,Placebo,control,333,248,74.0,0.0,0.0,248/333 (74%)
NCT05035095,Race,Other*,Race,categorical,,Oral semaglutide 50 mg,treatment,334,31,9.0,0.0,0.0,31/334 (9%)
NCT05035095,Race,Other*,Race,categorical,,Placebo,control,333,27,8.0,0.0,0.0,27/333 (8%)
NCT05035095,Ethnicity,Hispanic or Latino,Ethnicity,categorical,,Oral semaglutide 50 mg,treatment,334,14,4.0,0.0,0.0,14/334 (4%)
NCT05035095,Ethnicity,Hispanic or Latino,Ethnicity,categorical,,Placebo,control,333,13,4.0,0.0,0.0,13/333 (4%)
NCT05035095,Ethnicity,Not Hispanic or Latino,Ethnicity,categorical,,Oral semaglutide 50 mg,treatment,334,288,86.0,0.0,0.0,288/334 (86%)
NCT05035095,Ethnicity,Not Hispanic or Latino,Ethnicity,categorical,,Placebo,control,333,296,89.0,0.0,0.0,296/333 (89%)
NCT05035095,Ethnicity,Not reported,Ethnicity,categorical,,Oral semaglutide 50 mg,treatment,334,32,10.0,0.0,0.0,32/334 (10%)
NCT05035095,Ethnicity,Not reported,Ethnicity,categorical,,Placebo,control,333,24,7.0,0.0,0.0,24/333 (7%)
NCT05035095,Bodyweight,"Bodyweight, kg",,continuous,kg,Oral semaglutide 50 mg,treatment,334,0,0.0,104.5,22.0,104·5 (22·0)
NCT05035095,Bodyweight,"Bodyweight, kg",,continuous,kg,Placebo,control,333,0,0.0,106.2,22.3,106·2 (22·3)
NCT05035095,BMI,"BMI, kg/m2",,continuous,kg/m2,Oral semaglutide 50 mg,treatment,334,0,0.0,37.3,6.3,37·3 (6·3)
NCT05035095,BMI,"BMI, kg/m2",,continuous,kg/m2,Placebo,control,333,0,0.0,37.7,6.8,37·7 (6·8)
NCT05035095,Waist circumference,"Waist circumference, cm",,continuous,cm,Oral semaglutide 50 mg,treatment,334,0,0.0,112.6,13.6,112·6 (13·6)
NCT05035095,Waist circumference,"Waist circumference, cm",,continuous,cm,Placebo,control,333,0,0.0,114.5,15.4,114·5 (15·4)
NCT05035095,HbA1c,"HbA1c, %",,continuous,%,Oral semaglutide 50 mg,treatment,334,0,0.0,5.6,0.3,5·6 (0·3)
NCT05035095,HbA1c,"HbA1c, %",,continuous,%,Placebo,control,333,0,0.0,5.6,0.3,5·6 (0·3)
NCT05035095,HbA1c,"HbA1c, mmol/mol",,continuous,mmol/mol,Oral semaglutide 50 mg,treatment,334,0,0.0,37.5,3.6,37·5 (3·6)
NCT05035095,HbA1c,"HbA1c, mmol/mol",,continuous,mmol/mol,Placebo,control,333,0,0.0,37.9,3.7,37·9 (3·7)
NCT05035095,Fasting plasma glucose,"Fasting plasma glucose, mmol/L",,continuous,mmol/L,Oral semaglutide 50 mg,treatment,333,0,0.0,5.4,0.7,5·4 (0·7); n=333
NCT05035095,Fasting plasma glucose,"Fasting plasma glucose, mmol/L",,continuous,mmol/L,Placebo,control,331,0,0.0,5.5,0.5,5·5 (0·5); n=331
NCT05035095,Fasting serum insulin,"Fasting serum insulin, geometric mean (CV), pmol/L",,continuous,pmol/L,Oral semaglutide 50 mg,treatment,296,0,0.0,93.7,60.4,93·7 (60·4); n=296
NCT05035095,Fasting serum insulin,"Fasting serum insulin, geometric mean (CV), pmol/L",,continuous,pmol/L,Placebo,control,299,0,0.0,92.7,57.6,92·7 (57·6); n=299
NCT05035095,Prediabetes,Prediabetes†,,categorical,,Oral semaglutide 50 mg,treatment,334,132,40.0,0.0,0.0,132/334 (40%)
NCT05035095,Prediabetes,Prediabetes†,,categorical,,Placebo,control,333,130,39.0,0.0,0.0,130/333 (39%)
NCT05035095,Blood pressure,Systolic,Blood pressure,continuous,mm Hg,Oral semaglutide 50 mg,treatment,334,0,0.0,129.0,16.0,129 (16)
NCT05035095,Blood pressure,Systolic,Blood pressure,continuous,mm Hg,Placebo,control,333,0,0.0,130.0,15.0,130 (15)
NCT05035095,Blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Oral semaglutide 50 mg,treatment,334,0,0.0,82.0,11.0,82 (11)
NCT05035095,Blood pressure,Diastolic,Blood pressure,continuous,mm Hg,Placebo,control,333,0,0.0,83.0,11.0,83 (11)
NCT05035095,Pulse,"Pulse, bpm",,continuous,bpm,Oral semaglutide 50 mg,treatment,334,0,0.0,71.0,10.0,71 (10)
NCT05035095,Pulse,"Pulse, bpm",,continuous,bpm,Placebo,control,333,0,0.0,72.0,10.0,72 (10)
NCT05035095,Lipids,Total cholesterol,Lipids,continuous,mmol/L,Oral semaglutide 50 mg,treatment,332,0,0.0,5.0,20.7,5·0 (20·7); n=332
NCT05035095,Lipids,Total cholesterol,Lipids,continuous,mmol/L,Placebo,control,328,0,0.0,4.9,20.1,4·9 (20·1); n=328
NCT05035095,Lipids,HDL cholesterol,Lipids,continuous,mmol/L,Oral semaglutide 50 mg,treatment,331,0,0.0,1.3,24.7,1·3 (24·7); n=331
NCT05035095,Lipids,HDL cholesterol,Lipids,continuous,mmol/L,Placebo,control,326,0,0.0,1.3,23.3,1·3 (23·3); n=326
NCT05035095,Lipids,LDL cholesterol,Lipids,continuous,mmol/L,Oral semaglutide 50 mg,treatment,331,0,0.0,3.0,31.1,3·0 (31·1); n=331
NCT05035095,Lipids,LDL cholesterol,Lipids,continuous,mmol/L,Placebo,control,326,0,0.0,2.8,34.0,2·8 (34·0); n=326
NCT05035095,Lipids,VLDL cholesterol,Lipids,continuous,mmol/L,Oral semaglutide 50 mg,treatment,332,0,0.0,0.6,44.3,0·6 (44·3); n=332
NCT05035095,Lipids,VLDL cholesterol,Lipids,continuous,mmol/L,Placebo,control,328,0,0.0,0.6,50.9,0·6 (50·9); n=328
NCT05035095,Free fatty acids,Free fatty acids,,continuous,mmol/L,Oral semaglutide 50 mg,treatment,296,0,0.0,0.4,63.1,0·4 (63·1); n=296
NCT05035095,Free fatty acids,Free fatty acids,,continuous,mmol/L,Placebo,control,299,0,0.0,0.4,60.6,0·4 (60·6); n=299
NCT05035095,Triglycerides,Triglycerides,,continuous,mmol/L,Oral semaglutide 50 mg,treatment,332,0,0.0,1.4,44.8,1·4 (44·8); n=332
NCT05035095,Triglycerides,Triglycerides,,continuous,mmol/L,Placebo,control,328,0,0.0,1.4,52.2,1·4 (52·2); n=328
NCT05035095,High-sensitivity C-reactive protein,"High-sensitivity C-reactive protein, geometric mean (CV), mg/dL",,continuous,mg/dL,Oral semaglutide 50 mg,treatment,333,0,0.0,3.4,138.0,3·4 (138·0); n=333
NCT05035095,High-sensitivity C-reactive protein,"High-sensitivity C-reactive protein, geometric mean (CV), mg/dL",,continuous,mg/dL,Placebo,control,328,0,0.0,3.4,143.3,3·4 (143·3); n=328
NCT05035095,eGFR,"eGFR, geometric mean (CV), mL/min per 1·73 m²",,continuous,mL/min per 1·73 m²,Oral semaglutide 50 mg,treatment,334,0,0.0,96.1,17.0,96·1 (17·0)
NCT05035095,eGFR,"eGFR, geometric mean (CV), mL/min per 1·73 m²",,continuous,mL/min per 1·73 m²,Placebo,control,333,0,0.0,93.3,20.5,93·3 (20·5)
NCT05035095,IWQOL-Lite-CT scores,Physical Function,IWQOL-Lite-CT scores,continuous,,Oral semaglutide 50 mg,treatment,322,0,0.0,63.6,22.4,63·6 (22·4); n=322
NCT05035095,IWQOL-Lite-CT scores,Physical Function,IWQOL-Lite-CT scores,continuous,,Placebo,control,328,0,0.0,61.3,22.9,61·3 (22·9); n=328
NCT05035095,IWQOL-Lite-CT scores,Total,IWQOL-Lite-CT scores,continuous,,Oral semaglutide 50 mg,treatment,322,0,0.0,62.0,20.9,62·0 (20·9); n=322
NCT05035095,IWQOL-Lite-CT scores,Total,IWQOL-Lite-CT scores,continuous,,Placebo,control,328,0,0.0,60.4,19.9,60·4 (19·9); n=328
NCT05035095,SF-36v2 scores,Physical Functioning,SF-36v2 scores,continuous,,Oral semaglutide 50 mg,treatment,327,0,0.0,51.4,7.0,51·4 (7·0); n=327
NCT05035095,SF-36v2 scores,Physical Functioning,SF-36v2 scores,continuous,,Placebo,control,331,0,0.0,51.0,7.0,51·0 (7·0); n=331
NCT05035095,SF-36v2 scores,Physical Component Summary,SF-36v2 scores,continuous,,Oral semaglutide 50 mg,treatment,327,0,0.0,51.4,7.4,51·4 (7·4); n=327
NCT05035095,SF-36v2 scores,Physical Component Summary,SF-36v2 scores,continuous,,Placebo,control,331,0,0.0,51.0,7.4,51·0 (7·4); n=331
NCT05035095,SF-36v2 scores,Mental Component Summary,SF-36v2 scores,continuous,,Oral semaglutide 50 mg,treatment,327,0,0.0,54.8,6.1,54·8 (6·1); n=327
NCT05035095,SF-36v2 scores,Mental Component Summary,SF-36v2 scores,continuous,,Placebo,control,331,0,0.0,55.4,5.6,55·4 (5·6); n=331
NCT05035095,Comorbidities at screening,Hypertension,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,144,43.0,0.0,0.0,144/334 (43%)
NCT05035095,Comorbidities at screening,Hypertension,Comorbidities at screening,categorical,,Placebo,control,333,161,48.0,0.0,0.0,161/333 (48%)
NCT05035095,Comorbidities at screening,Dyslipidaemia,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,128,38.0,0.0,0.0,128/334 (38%)
NCT05035095,Comorbidities at screening,Dyslipidaemia,Comorbidities at screening,categorical,,Placebo,control,333,139,42.0,0.0,0.0,139/333 (42%)
NCT05035095,Comorbidities at screening,Obstructive sleep apnoea,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,45,13.0,0.0,0.0,45/334 (13%)
NCT05035095,Comorbidities at screening,Obstructive sleep apnoea,Comorbidities at screening,categorical,,Placebo,control,333,48,14.0,0.0,0.0,48/333 (14%)
NCT05035095,Comorbidities at screening,Knee or hip osteoarthritis,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,34,10.0,0.0,0.0,34/334 (10%)
NCT05035095,Comorbidities at screening,Knee or hip osteoarthritis,Comorbidities at screening,categorical,,Placebo,control,333,42,13.0,0.0,0.0,42/333 (13%)
NCT05035095,Comorbidities at screening,Asthma or chronic obstructive pulmonary disease,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,41,12.0,0.0,0.0,41/334 (12%)
NCT05035095,Comorbidities at screening,Asthma or chronic obstructive pulmonary disease,Comorbidities at screening,categorical,,Placebo,control,333,29,9.0,0.0,0.0,29/333 (9%)
NCT05035095,Comorbidities at screening,Thyroid disorder,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,33,10.0,0.0,0.0,33/334 (10%)
NCT05035095,Comorbidities at screening,Thyroid disorder,Comorbidities at screening,categorical,,Placebo,control,333,33,10.0,0.0,0.0,33/333 (10%)
NCT05035095,Comorbidities at screening,Glucose metabolism disorder,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,29,9.0,0.0,0.0,29/334 (9%)
NCT05035095,Comorbidities at screening,Glucose metabolism disorder,Comorbidities at screening,categorical,,Placebo,control,333,24,7.0,0.0,0.0,24/333 (7%)
NCT05035095,Comorbidities at screening,Liver disease,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,20,6.0,0.0,0.0,20/334 (6%)
NCT05035095,Comorbidities at screening,Liver disease,Comorbidities at screening,categorical,,Placebo,control,333,20,6.0,0.0,0.0,20/333 (6%)
NCT05035095,Comorbidities at screening,Gout,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,12,4.0,0.0,0.0,12/334 (4%)
NCT05035095,Comorbidities at screening,Gout,Comorbidities at screening,categorical,,Placebo,control,333,15,5.0,0.0,0.0,15/333 (5%)
NCT05035095,Comorbidities at screening,Reproductive system disorders,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,8,2.0,0.0,0.0,8/334 (2%)
NCT05035095,Comorbidities at screening,Reproductive system disorders,Comorbidities at screening,categorical,,Placebo,control,333,5,2.0,0.0,0.0,5/333 (2%)
NCT05035095,Comorbidities at screening,Coronary artery disease,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,6,2.0,0.0,0.0,6/334 (2%)
NCT05035095,Comorbidities at screening,Coronary artery disease,Comorbidities at screening,categorical,,Placebo,control,333,3,1.0,0.0,0.0,3/333 (1%)
NCT05035095,Comorbidities at screening,Kidney disease,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,4,1.0,0.0,0.0,4/334 (1%)
NCT05035095,Comorbidities at screening,Kidney disease,Comorbidities at screening,categorical,,Placebo,control,333,3,1.0,0.0,0.0,3/333 (1%)
NCT05035095,Comorbidities at screening,Cerebrovascular disease,Comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,1,0.0,0.0,0.0,1/334 (0%)
NCT05035095,Comorbidities at screening,Cerebrovascular disease,Comorbidities at screening,categorical,,Placebo,control,333,3,1.0,0.0,0.0,3/333 (1%)
NCT05035095,Number of comorbidities at screening,Five or more,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,12,4.0,0.0,0.0,12/334 (4%)
NCT05035095,Number of comorbidities at screening,Five or more,Number of comorbidities at screening,categorical,,Placebo,control,333,6,2.0,0.0,0.0,6/333 (2%)
NCT05035095,Number of comorbidities at screening,Four,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,12,4.0,0.0,0.0,12/334 (4%)
NCT05035095,Number of comorbidities at screening,Four,Number of comorbidities at screening,categorical,,Placebo,control,333,17,5.0,0.0,0.0,17/333 (5%)
NCT05035095,Number of comorbidities at screening,Three,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,40,12.0,0.0,0.0,40/334 (12%)
NCT05035095,Number of comorbidities at screening,Three,Number of comorbidities at screening,categorical,,Placebo,control,333,50,15.0,0.0,0.0,50/333 (15%)
NCT05035095,Number of comorbidities at screening,Two,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,90,27.0,0.0,0.0,90/334 (27%)
NCT05035095,Number of comorbidities at screening,Two,Number of comorbidities at screening,categorical,,Placebo,control,333,87,26.0,0.0,0.0,87/333 (26%)
NCT05035095,Number of comorbidities at screening,One,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,96,29.0,0.0,0.0,96/334 (29%)
NCT05035095,Number of comorbidities at screening,One,Number of comorbidities at screening,categorical,,Placebo,control,333,100,30.0,0.0,0.0,100/333 (30%)
NCT05035095,Number of comorbidities at screening,None,Number of comorbidities at screening,categorical,,Oral semaglutide 50 mg,treatment,334,84,25.0,0.0,0.0,84/334 (25%)
NCT05035095,Number of comorbidities at screening,None,Number of comorbidities at screening,categorical,,Placebo,control,333,73,22.0,0.0,0.0,73/333 (22%)
NCT04881760,Age,Age-yr,,continuous,years,Placebo Group,control,70,0,0.0,48.0,12.5,48.0±12.5
NCT04881760,Age,Age-yr,,continuous,years,1 mg,treatment,69,0,0.0,50.6,13.3,50.6±13.3
NCT04881760,Age,Age-yr,,continuous,years,"4 mg (ID, 2 mg)",treatment,33,0,0.0,50.8,11.9,50.8±11.9
NCT04881760,Age,Age-yr,,continuous,years,"4 mg (ID, 4 mg)",treatment,34,0,0.0,46.8,14.1,46.8±14.1
NCT04881760,Age,Age-yr,,continuous,years,"8 mg (ID, 2 mg)",treatment,35,0,0.0,46.1,13.5,46.1±13.5
NCT04881760,Age,Age-yr,,continuous,years,"8 mg (ID, 4 mg)",treatment,35,0,0.0,48.7,11.1,48.7±11.1
NCT04881760,Age,Age-yr,,continuous,years,"12 mg (ID, 2 mg)",treatment,62,0,0.0,45.8,12.2,45.8±12.2
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,Placebo Group,control,70,34,49.0,0.0,0.0,34 (49)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,1 mg,treatment,69,33,48.0,0.0,0.0,33 (48)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,"4 mg (ID, 2 mg)",treatment,33,16,48.0,0.0,0.0,16 (48)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,"4 mg (ID, 4 mg)",treatment,34,16,47.0,0.0,0.0,16 (47)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,"8 mg (ID, 2 mg)",treatment,35,17,49.0,0.0,0.0,17 (49)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,"8 mg (ID, 4 mg)",treatment,35,17,49.0,0.0,0.0,17 (49)
NCT04881760,Female sex,Female sex no. (%),Sex,categorical,,"12 mg (ID, 2 mg)",treatment,62,30,48.0,0.0,0.0,30 (48)
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,Placebo Group,control,70,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,1 mg,treatment,69,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,1,3.0,0.0,0.0,1 (3)
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,American Indian or Alaska Native,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,1,2.0,0.0,0.0,1 (2)
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,Placebo Group,control,70,2,3.0,0.0,0.0,2 (3)
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,1 mg,treatment,69,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,1,3.0,0.0,0.0,1 (3)
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Asian,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,1,2.0,0.0,0.0,1 (2)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,Placebo Group,control,70,8,11.0,0.0,0.0,8 (11)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,1 mg,treatment,69,6,9.0,0.0,0.0,6 (9)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,4,12.0,0.0,0.0,4 (12)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,2,6.0,0.0,0.0,2 (6)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,4,11.0,0.0,0.0,4 (11)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,1,3.0,0.0,0.0,1 (3)
NCT04881760,Race or ethnic group,Black,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,2,3.0,0.0,0.0,2 (3)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,Placebo Group,control,70,59,84.0,0.0,0.0,59 (84)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,1 mg,treatment,69,61,88.0,0.0,0.0,61 (88)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,29,88.0,0.0,0.0,29 (88)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,30,88.0,0.0,0.0,30 (88)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,30,86.0,0.0,0.0,30 (86)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,33,94.0,0.0,0.0,33 (94)
NCT04881760,Race or ethnic group,White,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,56,90.0,0.0,0.0,56 (90)
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,Placebo Group,control,70,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,1 mg,treatment,69,1,1.0,0.0,0.0,1 (1)
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Native Hawaiian or other Pacific Islander,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,Placebo Group,control,70,1,1.0,0.0,0.0,1 (1)
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,1 mg,treatment,69,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"4 mg (ID, 4 mg)",treatment,34,1,3.0,0.0,0.0,1 (3)
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"8 mg (ID, 2 mg)",treatment,35,0,0.0,0.0,0.0,0
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"8 mg (ID, 4 mg)",treatment,35,1,3.0,0.0,0.0,1 (3)
NCT04881760,Race or ethnic group,Multiple,Race or ethnic group,categorical,,"12 mg (ID, 2 mg)",treatment,62,2,3.0,0.0,0.0,2 (3)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,Placebo Group,control,70,22,31.0,0.0,0.0,22 (31)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,1 mg,treatment,69,23,33.0,0.0,0.0,23 (33)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,"4 mg (ID, 2 mg)",treatment,33,9,27.0,0.0,0.0,9 (27)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,"4 mg (ID, 4 mg)",treatment,34,14,41.0,0.0,0.0,14 (41)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,"8 mg (ID, 2 mg)",treatment,35,15,43.0,0.0,0.0,15 (43)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,"8 mg (ID, 4 mg)",treatment,35,12,34.0,0.0,0.0,12 (34)
NCT04881760,Hispanic or Latino ethnic group,Hispanic or Latino ethnic group - no. (%)†,Ethnicity,categorical,,"12 mg (ID, 2 mg)",treatment,62,22,35.0,0.0,0.0,22 (35)
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,Placebo Group,control,70,0,0.0,11.7,9.3,11.7±9.3
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,1 mg,treatment,69,0,0.0,13.7,12.9,13.7±12.9
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,"4 mg (ID, 2 mg)",treatment,33,0,0.0,15.6,12.5,15.6±12.5
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,"4 mg (ID, 4 mg)",treatment,34,0,0.0,11.5,8.2,11.5±8.2
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,"8 mg (ID, 2 mg)",treatment,35,0,0.0,12.8,9.6,12.8±9.6
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,"8 mg (ID, 4 mg)",treatment,35,0,0.0,15.2,12.3,15.2±12.3
NCT04881760,Duration of obesity,Duration of obesity-yr,,continuous,years,"12 mg (ID, 2 mg)",treatment,62,0,0.0,12.1,9.7,12.1+9.7
NCT04881760,Body weight,Body weight - kg,,continuous,kg,Placebo Group,control,70,0,0.0,109.2,20.9,109.2±20.9
NCT04881760,Body weight,Body weight - kg,,continuous,kg,1 mg,treatment,69,0,0.0,106.4,19.8,106.4±19.8
NCT04881760,Body weight,Body weight - kg,,continuous,kg,"4 mg (ID, 2 mg)",treatment,33,0,0.0,108.0,26.3,108.0±26.3
NCT04881760,Body weight,Body weight - kg,,continuous,kg,"4 mg (ID, 4 mg)",treatment,34,0,0.0,107.0,21.3,107.0±21.3
NCT04881760,Body weight,Body weight - kg,,continuous,kg,"8 mg (ID, 2 mg)",treatment,35,0,0.0,106.5,21.6,106.5±21.6
NCT04881760,Body weight,Body weight - kg,,continuous,kg,"8 mg (ID, 4 mg)",treatment,35,0,0.0,108.6,20.9,108.6±20.9
NCT04881760,Body weight,Body weight - kg,,continuous,kg,"12 mg (ID, 2 mg)",treatment,62,0,0.0,108.0,21.7,108.0±21.7
NCT04881760,BMI,BMI,,continuous,,Placebo Group,control,70,0,0.0,37.3,5.9,37.3±5.9
NCT04881760,BMI,BMI,,continuous,,1 mg,treatment,69,0,0.0,37.5,5.9,37.5±5.9
NCT04881760,BMI,BMI,,continuous,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,37.3,5.9,37.3±5.9
NCT04881760,BMI,BMI,,continuous,,"4 mg (ID, 4 mg)",treatment,34,0,0.0,37.4,4.7,37.4±4.7
NCT04881760,BMI,BMI,,continuous,,"8 mg (ID, 2 mg)",treatment,35,0,0.0,37.4,6.0,37.4±6.0
NCT04881760,BMI,BMI,,continuous,,"8 mg (ID, 4 mg)",treatment,35,0,0.0,37.0,5.5,37.0±5.5
NCT04881760,BMI,BMI,,continuous,,"12 mg (ID, 2 mg)",treatment,62,0,0.0,37.4,6.0,37.4±6.0
NCT04881760,BMI category,<30,BMI category,categorical,,Placebo Group,control,70,5,7.0,0.0,0.0,5 (7)
NCT04881760,BMI category,<30,BMI category,categorical,,1 mg,treatment,69,3,4.0,0.0,0.0,3 (4)
NCT04881760,BMI category,<30,BMI category,categorical,,"4 mg (ID, 2 mg)",treatment,33,0,0.0,0.0,0.0,0
NCT04881760,BMI category,<30,BMI category,categorical,,"4 mg (ID, 4 mg)",treatment,34,0,0.0,0.0,0.0,0
NCT04881760,BMI category,<30,BMI category,categorical,,"8 mg (ID, 2 mg)",treatment,35,2,6.0,0.0,0.0,2 (6)
NCT04881760,BMI category,<30,BMI category,categorical,,"8 mg (ID, 4 mg)",treatment,35,2,6.0,0.0,0.0,2 (6)
NCT04881760,BMI category,<30,BMI category,categorical,,"12 mg (ID, 2 mg)",treatment,62,2,3.0,0.0,0.0,2 (3)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,Placebo Group,control,70,24,34.0,0.0,0.0,24 (34)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,1 mg,treatment,69,26,38.0,0.0,0.0,26 (38)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,"4 mg (ID, 2 mg)",treatment,33,15,45.0,0.0,0.0,15 (45)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,"4 mg (ID, 4 mg)",treatment,34,16,47.0,0.0,0.0,16 (47)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,"8 mg (ID, 2 mg)",treatment,35,11,31.0,0.0,0.0,11 (31)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,"8 mg (ID, 4 mg)",treatment,35,14,40.0,0.0,0.0,14 (40)
NCT04881760,BMI category,>30 to <35,BMI category,categorical,,"12 mg (ID, 2 mg)",treatment,62,24,39.0,0.0,0.0,24 (39)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,Placebo Group,control,70,20,29.0,0.0,0.0,20 (29)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,1 mg,treatment,69,20,29.0,0.0,0.0,20 (29)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,"4 mg (ID, 2 mg)",treatment,33,7,21.0,0.0,0.0,7 (21)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,"4 mg (ID, 4 mg)",treatment,34,8,24.0,0.0,0.0,8 (24)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,"8 mg (ID, 2 mg)",treatment,35,12,34.0,0.0,0.0,12 (34)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,"8 mg (ID, 4 mg)",treatment,35,9,26.0,0.0,0.0,9 (26)
NCT04881760,BMI category,≥35 to <40,BMI category,categorical,,"12 mg (ID, 2 mg)",treatment,62,16,26.0,0.0,0.0,16 (26)
NCT04881760,BMI category,≥40,BMI category,categorical,,Placebo Group,control,70,21,30.0,0.0,0.0,21 (30)
NCT04881760,BMI category,≥40,BMI category,categorical,,1 mg,treatment,69,20,29.0,0.0,0.0,20 (29)
NCT04881760,BMI category,≥40,BMI category,categorical,,"4 mg (ID, 2 mg)",treatment,33,11,33.0,0.0,0.0,11 (33)
NCT04881760,BMI category,≥40,BMI category,categorical,,"4 mg (ID, 4 mg)",treatment,34,10,29.0,0.0,0.0,10 (29)
NCT04881760,BMI category,≥40,BMI category,categorical,,"8 mg (ID, 2 mg)",treatment,35,10,29.0,0.0,0.0,10 (29)
NCT04881760,BMI category,≥40,BMI category,categorical,,"8 mg (ID, 4 mg)",treatment,35,10,29.0,0.0,0.0,10 (29)
NCT04881760,BMI category,≥40,BMI category,categorical,,"12 mg (ID, 2 mg)",treatment,62,20,32.0,0.0,0.0,20 (32)
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,Placebo Group,control,70,0,0.0,115.1,13.9,115.1±13.9
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,1 mg,treatment,69,0,0.0,114.8,14.7,114.8±14.7
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,"4 mg (ID, 2 mg)",treatment,33,0,0.0,117.2,16.6,117.2±16.6
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,"4 mg (ID, 4 mg)",treatment,34,0,0.0,115.2,14.2,115.2±14.2
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,"8 mg (ID, 2 mg)",treatment,35,0,0.0,114.3,14.3,114.3±14.3
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,"8 mg (ID, 4 mg)",treatment,35,0,0.0,115.6,12.7,115.6±12.7
NCT04881760,Waist circumference,Waist circumference-cm,,continuous,cm,"12 mg (ID, 2 mg)",treatment,62,0,0.0,116.5,16.4,116.5±16.4
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,Placebo Group,control,70,26,37.0,0.0,0.0,26 (37)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,1 mg,treatment,69,27,39.0,0.0,0.0,27 (39)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,"4 mg (ID, 2 mg)",treatment,33,15,45.0,0.0,0.0,15 (45)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,"4 mg (ID, 4 mg)",treatment,34,10,29.0,0.0,0.0,10 (29)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,"8 mg (ID, 2 mg)",treatment,35,11,31.0,0.0,0.0,11 (31)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,"8 mg (ID, 4 mg)",treatment,35,15,43.0,0.0,0.0,15 (43)
NCT04881760,Prediabetes,Prediabetes no. (%),Prediabetes,categorical,,"12 mg (ID, 2 mg)",treatment,62,19,31.0,0.0,0.0,19 (31)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,Placebo Group,control,70,40,57.0,0.0,0.0,40 (57)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,1 mg,treatment,69,30,43.0,0.0,0.0,30 (43)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,"4 mg (ID, 2 mg)",treatment,33,15,45.0,0.0,0.0,15 (45)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,"4 mg (ID, 4 mg)",treatment,34,12,35.0,0.0,0.0,12 (35)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,"8 mg (ID, 2 mg)",treatment,35,12,34.0,0.0,0.0,12 (34)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,"8 mg (ID, 4 mg)",treatment,35,13,37.0,0.0,0.0,13 (37)
NCT04881760,Hypertension,Hypertension no. (%),Hypertension,categorical,,"12 mg (ID, 2 mg)",treatment,62,22,35.0,0.0,0.0,22 (35)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,Placebo Group,control,70,23,33.0,0.0,0.0,23 (33)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,1 mg,treatment,69,22,32.0,0.0,0.0,22 (32)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,"4 mg (ID, 2 mg)",treatment,33,14,42.0,0.0,0.0,14 (42)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,"4 mg (ID, 4 mg)",treatment,34,12,35.0,0.0,0.0,12 (35)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,"8 mg (ID, 2 mg)",treatment,35,11,31.0,0.0,0.0,11 (31)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,"8 mg (ID, 4 mg)",treatment,35,9,26.0,0.0,0.0,9 (26)
NCT04881760,Dyslipidemia,Dyslipidemia no. (%),Dyslipidemia,categorical,,"12 mg (ID, 2 mg)",treatment,62,19,31.0,0.0,0.0,19 (31)
